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ABSTRACT 
 
BIOENGINEERED PLATFORMS TO STUDY CARCINOMA CELL RESPONSE 
TO DRUG TREATMENT 
 
MAY 2016 
THUY VINH LUONG NGUYEN 
B.S., GEORGIA INSTITUTE OF TECHNOLOGY 
M.S., GEORGIA INSTITUTE OF TECHNOLOGY 
PH.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Shelly R. Peyton 
 
 The tumor extracellular matrix (ECM) plays an important role in facilitating 
tumor growth and mediating tumor cells' resistance to drugs. However, during drug 
development, potential chemotherapeutics are screened in plastic plates, which lack 
relevant ECM physicochemical cues. In order to improve drug development process, this 
dissertation includes the development of relevant 2D and 3D biomaterial systems that can 
be used to study carcinoma cell response to drug treatment. 
 A novel poly(ethylene glycol)-phosphorylcholine (PEG-PC) high-throughput 
biomaterial platform was developed to study how the ECM mechanochemical properties 
affect cancer cells' response to drug. The PEG-PC biomaterial is optically transparent, 
has a mechanical range from 1 to 10,000 kPa in Young's modulus, and allows easy 
coupling of cell adhesive proteins. When testing several breast and liver cancer cell lines 
 ix 
 
on PEG-PC gels that had different stiffnesses and integrin-binding sites, there was a 
significant increase in drug resistance with increasing substrate stiffness. It was found 
that this stiffness-induced drug resistance was independent of Rho-ROCK and EGFR 
signaling, but co-administration of a β1 integrin antibody, or an inhibitor to JNK, with 
sorafenib effectively eliminated the stiffness-mediated sorafenib resistance. Finally, 3D 
hydrogel systems, poly(N-isopropylacrylamide)-PEG (PNIPAAm-PEG) and PEG-
Maleimide, were utilized to create multi-cellular spheroids to study drug resistance in 3D. 
Both SkBr3s and MDA-MB-231s were tested with sorafenib, lapatinib, temsirolimus, and 
doxorubicin across varying moduli and geometry (plastic, 2D and 3D hydrogels, 
spheroid) in different medium conditions. For some drugs, the change in platform or 
medium was found to have the largest effect on the variation of the IC-50 than the change 
in modulus. Specifically, the IC-50s varied the most when SkBr3s were treated with 
sorafenib and temsirolimus and when MDA-MB-231s were treated with sorafenib and 
lapatinib. However, when treated with doxrorubicin, the IC-50s of both cell types were 
similar across all platforms. These results demonstrate the utility of tailored biomaterial 
systems to address basic questions related to tumor microenvironment and drug 
resistance in cancer, and highlight the importance of incorporating relevant ECM factors 
into drug testing.
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 The Impact Of Cancer On Human Health 
 In the U.S., the Centers for Disease Control (CDC) and the National Cancer 
Institute (NCI) reported more than 1 million cases of invasive cancers and more than 
574,000 cancer-related deaths for each of the year between 1999 and 2011 [1]. In 2015, 
the number of new cancer cases are projected to be 1.7 million with breast and prostate 
cancer as the most dominant types of cancer for women and men, respectively [2]. These 
two types of cancer have been the top two of cancer incidence (Figure 1.1) and are 
projected to remain at the same place in 2030 [3]. Currently, the overall cost of cancer 
care is projected to be $173 billion in 2020, an increase of 39% from 2010 [4]. In 
addition to the high cost of cancer treatment, cancer patients usually suffer devastating 
side effects from chemotherapy and radiation. Those side effects include: reduction in 
bone density, cardiotoxicity, cognitive deficits, distress, fatigue, infertility, pain, and 
pulmonary dysfunction [5]. Furthermore, cancer survivors usually suffer the fear of 
cancer recurrence (FCR), which is a major psychological problem that results in anxiety 
and depression; these psychological issues can deeply affect their quality of life and 
relationships [6,7]. 
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Figure 1.1 Trends in incidence rates for selected cancer by sex (U.S. 1975 - 2011). 
Prostate cancer has the highest incidence rate for male whereas breast cancer incidence 
rate is the highest for female. Figure adapted with permission from [2]. © 2012American 
cancer society, Inc. 
 
1.2 The Biology Of Cancer 
 A tumor develops as a result of unregulated cell growth. Cancerous tumors are 
those that are capable of metastasizing to distal tissues to form secondary tumors. A 
healthy cell has to go through many stages to acquire progressive transformation to a 
highly malignant cell [8,9]. This multiple step process includes the capability of 
sustaining growth factor supply through autocrine or paracrine signaling, continuing to 
divide indefinitely, reprogramming of cellular metabolism to sustain unlimited growth, 
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being insensitive to anti-growth signals, evading apoptosis and immune destruction, 
maintaining angiogenesis, invading local tissue and metastasizing to distal tissues. Two 
characteristics that allow normal cells to develop these hallmark capabilities are genetic 
mutations that alter many intracellular regulatory pathways and inflammation of the 
tissue microenvironment that promotes tumor growth  [9].  
 Although genetic mutation is one of the key factors for tumor development, a 
single mutated gene is not enough to drive cancer cell growth. However, certain inherited 
mutated genes can put a person at higher risk to develop cancers. Women who carry 
BRCA1 and BRCA2 mutations have higher risks of having breast and ovarian cancers 
[10]. For example, by the age of 70, the risks of having breast cancer are 71% and 84% 
for BRCA1 and BRCA2 carriers, respectively [10]. However, inherited mutations in APC 
and DNA mismatch repair (MMR) genes only account for 4 - 6% of colorectal cancer 
(CRC) incidence in patients with family history of CRC [11]. In many cancers, multiple 
mutations are required for tumor cells to acquire growth advantage, and the majority of 
those are somatic mutations, which develop during a person's lifetime. For instance, the 
development of CRC starts with mutations in the APC gene, which results in early 
adenoma;   then subsequent mutations in K-RAS, p53, SMAD4 lead to cancer [12,13]. 
Thousands of somatic mutations in protein kinases, which are molecular targets of many 
current therapies, have been identified in many human cancers [14,15]. However, only a 
portion of these mutations are considered to be 'driver' mutations, which confer growth 
advantage, whereas the others are considered to be 'passenger' mutations, which do not 
confer growth advantage [15].  
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 Besides genetic mutations, inflammation in the tissue microenvironment can give 
rise to cancer development. Infection and chronic inflammation can create a 
microenvironment that fosters cancer cell proliferation, survival and invasion [16]. For 
instance, human papillomavirus (HPV) infection can result in oropharyngeal squamous 
cell carcinomas [17], head and neck squamous cell carcinomas [18], and cervical cancer 
[19]. Chronic hepatitis B or C virus (HBV or HCV) infection often leads to long-term 
inflammation and development of liver fibrosis and cirrhosis [20–22] followed by 
hepatocellular carcinoma [23]. Chronic infection can trigger the release of many pro-
inflammatory cytokines/chemokines (TNF-α, TGF-β1, etc) that can recruit many immune 
cells (neutrophils, monocytes, macrophages, mast cells, etc) that infiltrate the tissue in 
order to fight against the infection [16]. If the infection is chronic, the long-term presence 
of these cells can trigger a continuous production of cytokines, cytotoxic mediators 
(reactive oxygen species or ROS), and soluble mediators of cell killing (TNF-α, 
interleukins, and interferons) [16]. ROS can cause DNA damage and mutations, and 
many of these chemokines can cause epigenetic alterations and promote tumor cell 
growth, angiogenesis, and metastasis [16,24,25]. The presence of ROS and inflammatory 
cytokines can activate local cells to modify the extracellular matrix and release many 
factors that are in favor of tumor development and exacerbate the tissue inflammation 
[26,27].     
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1.3 Drug Resistance In Cancer  
1.3.1 Adaptive drug resistance 
 Adaptive drug resistance is the ability of a cell to adapt to treatment after initial 
exposure. Tumor cells can become resistant to drugs by increasing efflux, increasing 
mutations, activating cell survival pathways, inactivating death signaling pathways, 
enabling DNA-damage repair, and triggering autophagy (Figure 1.2) [28].  
 In order to change the rate of drug efflux, cancer cells upregulate expression of P-
glycoproteins transporters that can detect and pump out cytotoxic molecules such as 
doxorubicin or taxol as they cross the plasma membrane [29]. For drugs that require 
receptors or transporters to enter the cells, selective resistant cells harbor mutations that 
alter the function of these transporters, thus eliminating the intracellular drug uptake [29].  
 Kinase inhibitors have become more popular in cancer treatment due to their 
lower side-effects than conventional cytotoxic chemotherapy [30]. Cancer cells can 
acquire adaptive resistance to many kinase inhibitors by activating receptor tyrosine 
kinases (RTKs) and their downstream signaling pathways to enhance survival. For 
instance, activations of MET and AXL receptors were identified as mechanisms for 
resistance to trastuzumab and lapatinib in HER2-overexpressing breast cancer cells 
[31,32]. EGFR and PI3K/Akt activation promoted resistance of hepatocellular carcinoma 
cells to sorafenib [33,34]. Triple-negative breast cancer cells that were treated with a 
MEK inhibitor resulted in a rapid kinome reprogramming in which multiple RTKs and 
downstream signaling pathways were activated to induce drug resistance [35]. In 
melanoma, activation of the Akt pathway could mediate resistance to BRAF inhibitor 
[36]. Squamous cancer cells can resist gefitinib, an EGFR inhibitor, by increasing 
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phosphorylation of  IGFR, thus activating PI3K/Akt to enhance cell growth [37]. 
Moreover, cancer cells can also develop adaptive resistance to kinase inhibitors through 
mutations that can change kinase binding domains, thus avoiding inhibitor binding [30]. 
Chronic myelogeneous leukaemia (CML) tumor cells can amplify BCR-ABL genes to 
compensate for the loss of Bcr-Abl, which is inhibited by imatinib [38]. 
 Besides increasing survival pathways, cancer cells can also regulate apoptotic 
pathways through expression of anti-apoptotic molecules in Bcl-2 family such as Bcl-2 
and Bcl-XL [39,40]. Loss of function of pro-apoptotic molecules such as Bax and Bak 
can lead to complete resistance to the powerful chemotherapeutic drug cisplatin [41]. 
Overexpression of Bcl-2 and downregulation of Bax/Bak is present in many types of 
cancers [42]. In addition, the epithelial-to-messenchymal (EMT) transition can trigger a 
cancer-stem-cell-like phenotype and mediate drug resistance [43]. 
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Figure 1.2 Schematic of different mechanisms of acquired drug resistance. Cancer 
cells can resist to (A) chemotherapeutic drugs that trigger DNA damages and (B) targeted 
drugs that inhibit kinase activities through multiple intracellular changes. Figure adapted 
with permission from [28]. © 2013 MacMillan Publishers Inc. 
 
  
A 
B 
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1.3.2 Microenvironment-induced resistance 
 The tumor microenvironment is known to play an important role in providing a 
niche to nurture the growth of cancer cells and mediate signals that allow them to survive 
chemotherapeutic treatment [44]. Cancer cells can receive signals from the tumor 
microenvironment through mechanical (ECM stiffening) and biochemical cues (Figure 
1.3). 
 
Figure 1.3 Tumor microenvironment and cancer development. The interaction 
between tumor cells and the microenvironment are important in regulating cancer cells' 
response to drugs. Figure adapted with permission from  [45]. © 2012 Elsevier, Inc. 
1.3.2.1 Extracellular matrix stiffening and cancer progression 
 During tumor progression, stromal fibroblasts, which differentiate into 
myofibroblasts [46], and cancer-associated fibroblasts (CAF) [47], remodel the ECM by 
breaking down the basement membrane and depositing fibril forming collagens [48–50]. 
The increase in crosslinked fibrous collagens results in tissue stiffening [50–52], which 
stimulates cancer cell proliferation [52,53], invasion and intravasation  [54–56], disrupts 
 9 
 
cell-cell adhesion [57], and alters sensitivity to growth factors [58], while simultaneously 
limiting the diffusion of therapeutic agents into the tumor [59].   
 Mechanotransduction is the process through which cells convert mechanical 
stimuli to biochemical signals that can subsequently regulate cellular function. 
Mechanotransduction is mediated through integrin binding of cells to ECM proteins. 
Integrins are heterodimers composed of α- and β-subunits. Different heterodimerizations 
of α- and β-subunits are required when the cells bind to different ECM proteins [60]. 
Binding of integrins to ECM proteins can mediate many different downstream signaling 
pathways such as PI3K/Akt and Ras/Raf/ERK to promote cell survival and proliferation 
or Rho/ROCK to alter cell motility (Figure 1.4) [61], and integrin binding can also induce 
the drug resistance of cancer cells to other chemotherapeutic drugs [62]. Expression of α6 
[63], β1 [64–68], and β6 [69] are known to induced chemoresistance in breast and colon 
cancers. Hence, a change in adhesive ECM proteins in the tissue microenvironment can 
confer resistance to chemotherapeutics via integrin-mediated signaling. ECM stiffening 
due to matrix crosslinking can induce integrin clustering, which leads to the formation of 
focal adhesions [70]. There are 180 proteins associated with focal adhesions; many of 
these are cytoskeletal proteins and signaling proteins such as kinases, phosphatases, and 
regulators of GTPases [71]. Therefore, focal adhesions play a role as cellular 
mechanosensors that transduce signals from the ECM to regulate cell behavior. The Rho 
GTPase family contains many key regulators of the actin cytoskeleton. The most well-
studied members of the family are Rho, Rac1, and cdc42, which control the formation of 
stress fibers, lamellipodia, and filopodia, respectively [72]. Both Rho and Rac1 are 
required for the formation of focal adhesions [73]. The formation of focal adhesions can 
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also activate focal adhesion kinase (FAK), which intensifies both the oncogene HER2-
mediated PI3K and ERK signaling pathways, to promote malignant transformation 
[52,53,70]. Activated FAK also promotes 3D invasiveness and facilitates cytoskeletal 
remodeling dynamics and contractile force generation [74].   
 Furthermore, stiffening of tumor tissue leads to the compression of blood vessels, 
which limits the delivery chemotherapeutic agents and the access of immune cells to kill 
tumor cells [75]. Hypoxic environments can also select for a subpopulation of cells that 
can survive harsh environments, thus they tend to be resistant to chemotherapeutics and 
radiation [75–77].   
 
Figure 1.4 Representative downstream signaling pathways that can be mediated 
through integrin binding. FN: Fibronectin, PI3K: Phosphoinositide 3-kinase, ILK: 
Integrin-linked kinase, Pax: paxillin, MEK: Mitogen-activated protein kinase kinase, 
ERK: Extracellular signal-regulated kinase, MLCK: Myosin light-chain kinase, MLC: 
Myosin light chain, Cas: Crk associated substrate, RAC-1: Ras-related C3 botolinum 
toxin substrate 1, PAK: p21 protein-activated kinase 1, WAVE: Wiskott-Aldrich 
syndrome family protein. Figure adapted with permission from [74]. © 2013 IOP 
publishing Ltd. 
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1.3.2.2 Biochemical factors and cancer progression  
 Within tumor tissue, multiple biochemical cues, which are pre-existing or made 
by tumor cells and other cell types, can mediate survival signals to tumor cells. These 
biochemical cues are growth factors, cytokines, and other factors that are released from 
different cell types in the tumor microenvironment. Interactions of tumor cells with these 
biochemical cues are known to enhance their proliferation, survival and invasion [78–80]. 
 Certain stromal growth factors mediate cell proliferation in the presence of 
otherwise powerful chemotherapeutic drugs. For example, hepatocyte growth factor 
(HGF) can impart resistance to vemurafenib in melanoma [81,82], and TGF-β can induce 
the expansion of cancer stem-like cells, which are responsible for chemotherapy-
resistance and relapse [83]. These growth factors are generally thought to be released by 
local stromal fibroblasts, which upon DNA-damage from treatments with a combination 
of mitoxantrone and docetaxel or radiation, stimulate prostate cancer cell proliferation 
and invasion through β-catenin signaling [84]. Cancer cells can also produce matrix 
metalloproteinases (MMP) to break down the ECM, which allows them to invade the 
local tissues for metastasis [85,86]. This ECM breakdown also allows cancer cells to 
access to matrix-bound growth factors such as EGF and TGF-β [78].   
 In addition to soluble growth factors, the presence of cytokines and other cellular 
secreted factors play a role in cancer cell drug resistance and invasion. The inflammatory 
tumor microenvironment recruits many immune cells such as macrophages, dendritic 
cells, T cells, and natural killer cells, and these infiltrated immune cells are the major 
source of cytokine production [87]. Some cytokines have an anti-tumor effect whereas 
some promote tumor development [24,88]. Interleukin 8 (IL-8) is known to mediate 
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breast cancer cell migration and invasion [89,90]. IL-8 and VEGF autocrine signaling can 
induce EMT, which results in drug resistance, and invasiveness [91]. IL-6, IL-17, and IL-
23 are also known to enhance tumor progression [24]. IL-4 was also found to mediate 
drug resistance in colon cancer stem cells [92]. Tumors grown from drug resistant cells, 
which had characteristics of cancer stem cells, were found to have elevated levels of 
cytokines, angiogenic and growth factors such as VEGF, bFGF, IL-6, IL-8, HGF, PDGF-
BB, G-CSF, and SCGF-β [93].  
1.4 Biomaterial Platforms For Cancer Studies 
1.4.1 The cost of drug development  
 Part of the incredible cost of cancer care is due to the high price tag of cancer 
drugs. It costs over $1 billion to bring a new drug to the market, and the success rate is 
approximately 10% [94]. The major reason for this low overall success rate and 
unimaginable cost is due to the limitation of preclinical cancer models, which are not 
predictive of human outcomes [94]. Typically, a drug development process will start with 
the identification of a biologically relevant target that drives the disease progression, then 
followed by a high-throughput screening of many small molecules or biologics. The 
molecules that emerge from the high-throughput screening are further optimized and 
tested on relevant animal models before entering clinical trials. However, many 
compounds that show efficacy during high-throughput screening do not show similar 
results when subsequently tested in vivo on animals or humans. This highly inefficient in 
vitro high-throughput screening increases not only the cost but also the drug development 
time, which is approximately 14 years on average (Figure 1.5) [95]. Currently, the high-
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throughput screening is usually performed with cells on plastic plates. Given the 
important roles of the ECM's mechanochemical signals in regulating cancer cell growth 
and their drug response as discussed earlier, it is critical to have an in vitro, high-
throughput biomaterial drug- testing platform that can capture these relevant 
mechanochemical cues. 
   
Figure 1.5 An outline of the standard drug development pipeline. Figure adapted with 
permission from [95]. © 2004 MacMillan Publishers Inc. 
1.4.2 Hydrogels for mimicking tumor microenvironment 
 Hydrogels are porous hydrophilic materials. Due to their hydrophilicity and 
biocompatibility, hydrogels are widely used for many biomedical applications from drug 
delivery to tissue engineering [96], such as how cell and matrix interaction governs stem 
cell fate on 2D [97] and in 3D [98]. In addition, hydrogels have been used  as platforms 
to study many biological phenomena in human diseases, such as cell migration [99] in 2D 
[100–102] and 3D [103–105], cellular response to drug treatment in ovarian cancer [106] 
and melanoma [107]. 
 Hydrogels are typically derived from natural or synthetic polymers. Common 
natural polymers include hyaluronic acid, chitosan, collagen, fibrin, agarose, alginate 
[108]. Some of the natural polymers such as collagen, fibrin, and hyaluronic acid are 
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components of mammalian ECM, thus they also contain many integrin binding sites for 
cell adhesion. On the other hand, chitosan, alginate, and agarose are polysaccharides-
derived from other natural sources (algae, chitin, etc), and they do not contain integrin 
binding sites. Natural polymers can be physically crosslinked to form hydrogels. 
Depending on the type of polymer, different methods can be utilized to induce physical 
crosslinking such as warming/cooling the polymer solution, mixing polyanion with 
polycation or with mutivalent ions of opposite charge, and changing pH [96]. However, 
hydrogels formed from these natural polymers are degradable over time through different 
mechanisms [108], and it is not possible to independently control the amount of binding 
sites and the material mechanical property. Increasing or decreasing the number of 
adhesive sites also increases or decreases the mechanical stiffness since the mechanical 
properties of these hydrogel are dependent on protein concentration. Therefore, some 
groups have spurred the development of natural- polymer hydrogels that allow 
independent control of binding sites and mechanical property. For example, hyaluronic 
acid can be modified with methacrylate and maleimide functional groups, and these 
functional groups can be chemically crosslinked by DL-dithiothreoitol (DTT) or Ultra 
Violet radiation [109,110].  
 In contrast, synthetic polymer hydrogels allow independent control over 
mechanical and adhesive properties. Synthetic hydrogels are derived from derivatives of 
synthetic polymers such as poly(hydroxyethyl methacrylate) (PHEMA), poly- (ethylene 
glycol) (PEG),  poly(vinyl alcohol) (PVA), poly(ethylene oxide) (PEO), polyacrylamide 
(PAAm), etc [108]. Polymerization methods include chain-growth polymerization 
through free-radical polymerization and step-growth polymerization through Michael-
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addition reactions [111]. Since synthetic polymers do not contain cell binding sites like 
natural polymers, peptides or full-length proteins that mediate cell adhesion need to be 
incorporated into the gels. Therefore, the mechanical properties can be modified through 
changing of polymer concentration or cross-link density without affecting the number of 
cell binding site. Hydrogel surfaces can be functionalized with cell binding peptides or 
full-length proteins following different bioconjugate methods such as azide-alkyne 
"click" chemistry [112]. In three dimensions, both cell binding peptides or degradable 
peptides can be incorporated into the hydrogel system [111,113,114]. Therefore, the 
ability to incorporate specific binding or degradable peptides in a controllable manner 
allows synthetic hydrogel to be tailored for a specific study. For example, both RGD cell 
binding peptide and MMP-degradable crosslinkers were incorporated into 3D hydrogel 
systems to study how matrix stiffness affects the progression of glioblastoma [115], and 
an in situ fluorogenic MMP sensor peptide was used to investigate how drug treatment 
influences MMP activity of metastatic melanoma cells in three dimensions [116]. RGD is 
the binding site of fibronectin, and many other cell binding peptides from other proteins 
are also identified [62]. 
 In addition, composite hydrogels that are made from both natural and synthetic 
polymers have been used in many studies. For instance, composite hydrogels of PEG and 
collagen were used as scaffolds for immune cells [117] and pancreatic cancer cells [118]. 
Hybrid PEG-based hydrogels can also be created by combining PEG polymers with the 
recombinant proteins containing both fibrinogen and collagen binding sites [119]. 
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1.5 Hypothesis 
 As depicted in Figure 1.3, the tumor microenvironment plays an important role in 
promoting the growth of cancer cells and mediating resistance to chemotherapeutics. The 
change in the ECM properties during disease progression results in mechanical and 
biochemical changes that profoundly affect cell behaviors via alterations in intracellular 
signaling (Figure 1.4). Since many novel targeted drugs have been designed to inhibit 
specific intracellular pathways as a mechanism to stop cancer cell growth, it is not well 
understood how both mechanical and biochemical changes can lead to alterations in 
downstream intracellular signaling pathways that ultimately hamper the effectiveness of 
targeted drugs. I hypothesize that cancer cells become resistant to chemotherapeutics 
via interaction with the physicochemical cues from the tumor ECM (Figure 1.6). The 
research presented in this dissertation aims to elucidate the mechanisms by which the 
tumor ECM contributes to drug resistance in both 2D and 3D. Testing this hypothesis 
requires the development of a high-throughput platform, which can capture the ECM 
mechanochemical properties, to facilitate the drug screening process. These 2D and 3D 
platforms were made with synthetic hydrogels that allow tunable mechanical properties 
and easy functionalization of full-length ECM proteins or short peptides that contain 
binding sites found in natural ECM proteins. Anti-cancer drugs were tested with cells 
seeded on the hydrogel surface or encapsulated within the hydrogels. Furthermore, the 
intracellular signaling that is mediated by the interactions with these 2D and 3D 
platforms were examined. 
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Figure 1.6 An outline of governing hypothesis. 
1.6 Objectives For Dissertation 
 I hypothesize that the mechanical and biochemical properties of the ECM can 
influence cancer cell response to chemotherapeutics. The research presented in this 
dissertation were outlined as specific aims in Figure 1.7. 
 
            
 
 
 
 
 
 
Dead or Alive? 
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Figure 1.7 Objectives for Dissertation. Chapter 2 describes aim 1, where the novel 
PEG-PC biomaterial was created for mechanobiology. Chapter 3 describes aim 2, where 
high-throughput platforms were designed from PEG, PEG-PC, and PAA, and cell 
response to drug was examined as a function of integrin binding. Chapter 4 describes aim 
3, where cancer cell response to sorafenib was studied across varying conditions. Finally, 
chapter 4 describes aims 4 and 5, where both PNIPAAm-PEG and PEG-MAL were used 
as platforms for 3D culture, and cell response to drug was studied with different 
platforms. 
 
 
Hypothesis 
Mechanochemical properties of 
the ECM regulate cancer cell 
response to chemotherapeutics 
Aim 1: Design novel 
biomaterial for mechanobiology 
on 2D 
Aim 3: Study cellular response 
to drugs on varying material 
stiffness and cell-binding 
conditions 
Aim 2: Design novel 2D high 
through-put platforms 
Aim 4: Design novel 
biomaterial platforms for 3D 
culture of cancer cells 
Aim 5: Examine cellular 
response to drugs across 
multiple types of platform 
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1.7 Significance 
 The mechanical and biochemical cues from the ECM regulate many cellular 
behaviors including proliferation, differentiation, and migration. However, how these 
physicochemical cues together affect cell response to chemotherapeutics is not well 
understood. The research presented in this dissertation addresses this question at the sub-
cellular level across varying geometries, material properties, and cell-binding ligands. 
Insights gained from this research will not only provide better understanding of cell-
matrix and drug interactions, but also aid in future design of biomaterials to study many 
other diseases. The novel PEG-PC gel developed from this research has a mechanical 
range that matches or exceeds any previously reported hydrogel system and can be served 
as an ideal platform for future studies in regenerative medicine and disease mechanisms. 
The high-throughput biomaterial platforms created from this research are promising 
predictive tools for future drug screening, and help to facilitate the process of drug 
development. 
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CHAPTER 2 
 
SYNTHESIS OF PEG-PC BIOMATERIAL SYSTEM AND 
MECHANICAL/STRUCTURAL CHARACTERIZATION 
 
2.1 Abstract 
 Both synthetic and natural biomaterial platforms are commonly used as mimics of 
in vivo tissues for in vitro studies in mechanobiology. These biomaterial platforms can be 
tailored to capture many aspects of the in vivo ECM, therefore studies conducted using 
these platforms are potentially more predictive of in vivo outcomes than traditional tissue 
culture plastic plates. Synthetic biomaterials allow the mechanical and adhesive 
properties to be tuned independently, as opposed to natural biomaterials.  In response to 
the needs of new synthetic biomaterials with improved properties, a new class of 
hydrogels was created by combing PEG and phosphorylcholine (PC). The resulting 
hydrogels have an extremely wide range of tunable mechanical properties, with small 
mesh sizes and high optical transparency. As a proof of concept, the stiffness sensing of 
multiple cell lines on the hydrogels was studied through quantification of focal adhesion 
properties. This novel PEG-PC biomaterial can be useful for many applications in 
studying mechanobiology.  
 38 
 
2.2 Introduction 
 Both naturally derived polymers and chemically synthetic polymers are widely 
used as biomaterial platforms to support cell culture in two and three dimensions (2D, 
3D). The two most common  naturally derived materials are collagens and matrigel. Both 
of these materials contain native binding sites for cell adhesion; however, it is not 
possible to independently control the amount of binding sites and the material mechanical 
property, i.e. increasing or decreasing the number of adhesive sites also increases or 
decreases the mechanical stiffness. On the other hand, synthetic polymer hydrogels allow 
independent control over mechanical and adhesive properties. The two most commonly 
used synthetic hydrogels are made from either polyacrylamide (PAA) or poly(ethylene 
glycol) (PEG) polymers. The PAA hydrogel was the first popularized biomaterial used in 
mechanobiology studies. However, these gels have limited mechanical range and are not 
suitable for three-dimensional (3D) studies. PEG-based hydrogels have a modulus of 20-
500 kPa [1,2], and can be engineered to contain specific hydrolytic [3,4] or enzymatic 
degradable sites [5] for 3D cell culture. Both PEG and PAA can be coupled with short 
peptides or full-length proteins of interest.  
 Phosphorylcholine is a zwitterion that locates at the outer membrane of the cells, 
providing an inert surface for many biological reactions [6]. 2-methacryloyloxyethyl 
phosphorylcholine (MPC) is a monomer containing a phospholipid polar group. Co-
polymers that incorporated MPC were shown to suppress clot formation and reduce 
platelet adhesion due to its anti-protein adsorption property, which is a result of 
enhancing surface hydrophilicity [7]. MPC co-polymers were also shown to be more anti-
protein adsorptive than  poly[2-hydroxyethyl methacrylate (HEMA)] due to larger free 
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water fraction on the surface [7].  Therefore, inclusion of a PC zwitterion group into a 
PEG hydrogel can potentially create a more hydrophilic biomaterial and prevent the 
proteins from culture serum to passively adsorb to the hydrogel surface and influence cell 
behavior. 
 Ishihara and co-workers investigated the mechanical property of MPC polymer 
hydrogels, which were cross-linked either with N,N'- methylenebisacrylamide (BIS) or  
2-(methacryloyloxy)ethyl-[N-(2-methacryloyloxy)ethyl]phosphorylcholine (MMPC). 
They found that MMPC showed higher cross-linking reactivity with MPC than BIS, 
therefore improving the tensile property of the material [8]. This result suggests that 
incorporation of PC groups into a hydrogel network can potentially increase the 
mechanical properties. MPC monomers can be incorporated into a hydrogel network 
following free-radical polymerization [9] or Michael addition [10]. The work in this 
chapter describes the creation of a novel "PEG-PC" hydrogel by co-polymerizing MPC 
with PEG dimethacrylate (PEGDMA) following free-radical polymerization. The 
resulting PEG-PC hydrogels have a mechanical range that spans four orders of magnitude 
(1-10,000 kPa), which matches or exceeds any previously reported hydrogel system,  and 
have an improved anti-protein adsorption property compared to PEGDMA hydrogels [9]. 
Here, the bulk mechanical properties of PEG-PC hydrogels are measured using a 
compression test in which the hydrogels, in the absence of cells, are deformed at a 
constant strain rate. 
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2.3 Materials And Methods 
2.3.1 PEG-PC hydrogel formation 
 2-methacryloyloxyethyl phosphorylcholine (Sigma-Aldrich) (MPC) was 
dissolved in phosphate buffered saline (PBS) to make a final concentration of 0.6 M (17 
wt %). PEGDMA (average Mn 750, Sigma-Aldrich, St. Louis, MO), varied between final 
concentrations of 7.4 mM and 0.7 M (0.5−55 wt %), was added into the MPC solution to 
create various PEG-PC polymer hydrogel precursor solutions. Solutions were degassed 
for 30 s with nitrogen and sterilized using a 0.2 μm syringe filter (Thermo Fisher 
Scientific, Waltham, MA). Depending on the desired format, two different free radical 
initiators were used for polymerization. To cure under UV light, 0.8 wt % Irgacure 2959 
(BASF, Ludwigshafen, Germany) was added, and gel formation was induced with a 
Spectroline High-Intensity UV Lamp at 365 nm (Model no. SB-100P, Westbury, NY), 
3.5 in. from the gel for 7 min. To form hydrogels in the absence of UV light, 0.05 wt % 
ammonium persulfate (APS) and 0.125 vol % tetramethylethylenediamine (TEMED, 
Bio-Rad Laboratories, Hercules, CA) were added, and gels were polymerized under 
nitrogen for 10 min. 
2.3.2 Hydrogel mechanical and structural characterization 
 PEG-PC hydrogel cylinders for mechanical compression testing were formed in 
5-mm Teflon molds and swelled in PBS for 48 h. Post swelling, hydrogel dimensions 
were measured with digital calipers, and mechanical compression tests were performed 
with a TA Instruments (New Castle, DE) AR-2000 rheometer at a 2 μm/s strain rate. The 
Young’s modulus (E) for each hydrogel was calculated by plotting the measured normal 
force between 0 and 4% strain and dividing the slope of the best-fit linear regression by 
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the hydrogel cross-sectional area. The Young’s modulus was obtained for 4 or more 
hydrogels for each PEGDMA concentration. To determine an approximate average mesh 
size as a function of PEGDMA cross-linker content with constant PC content, hydrogels 
were swelled in PBS for 48 h, then weighed, fully lyophilized, and weighed again. The 
average mesh size, ξ, of the PEG-PC hydrogels was determined as a function of 
PEGDMA cross-linker concentration according to the Flory theory as modified by Canal 
and Peppas: 
𝜉 = υ2,s−13(r̅2)1/2   
where 𝜐2,𝑠 is the swollen volume fraction of polymer and (r̅2)1/2 is the average end-to-
end distance of the PEGDMA cross-linker. 
2.3.3 Making gels on coverslips and protein functionalization 
 18 mm glass coverslips (Thermo Fisher Scientific, Waltham, MA) were plasma 
treated (Harrick Plasma, Ithaca, NY) and subsequently methacrylate-silanized with 2 
vol% 3-(trimethoxysilyl) propyl methacrylate (Sigma-Aldrich, St. Louis, MO) in 95% 
ethanol (adjusted to pH 5.0 with glacial acetic acid) for 5 min, washed 3 times with 100% 
ethanol, and dried at 120 °C for 15 min. To make thin PEG-PC hydrogels with even 
heights and suitable for microscopy, 80 μL PEG-PC hydrogels were polymerized with 
APS and TEMED between a methacrylated-silanized coverslip and an untreated coverslip 
for 20 min on the bench. After polymerization, the hydrogels were allowed to swell in 
PBS, and the non-treated coverslips were removed easily with fine forceps.   
 The gel surfaces can be coupled with the heterobifunctional cross-linker, which 
contains a highly amine-reactive functional group for covalent linkage to a variety of 
integrin-binding proteins. Two heterobifunctional cross-linkers used were sulfo-
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SANPAH (ProteoChem, Denver, CO) and acrylate-poly(ethylene glycol)-succinimidyl 
valerate (PEG-SVA; Laysan Bio, Arab, AL). With sulfo-SANPAH,  swollen gels on 
coverslips were transferred to 12-well tissue culture dishes and treated with sulfo-
SANPAH (0.3 mg/mL in pH 8.5 HEPES buffer) under UV light for 15 min, rinsed twice 
with HEPES buffer, and followed immediately by incubation with proteins overnight. 
With PEG-SVA, the cross-linker was added to the PEG-PC prehydrogel solution at 0.11 
wt %. This method incorporates an amine reactive group into the bulk of the hydrogel 
instead of isolating the reaction at the surface like sulfo-SANPAH. The protein used was 
type I collagen (rat tail, Life Technologies), recombinant human collagen III (FibroGen, 
San Francisco, CA), and human plasma fibronectin (EMD Millipore, Billerica, MA). 
Protein solution was made in sterile PBS and adjusted to pH 3 to prevent collagen 
gelation. Post protein reaction, hydrogels were washed 3 times with sterile PBS with 
shaking and then UV sterilized for 60 min before cell seeding. 
2.3.4 Cell culture 
 All supplies were purchased from Life Technologies (Carlsbad, CA) unless 
otherwise noted. Human breast cancer cell lines (MDA-MB-231 and SkBr3) were 
generous gifts from Dr. Shannon Hughes at the Massachusetts Institute of Technology, 
and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) at 37ºC and 5% 
CO2.  Human hepatocellular carcinoma (HCC) cells (HEP3Bs, American Type Culture 
Collection, Manassas, VA) were cultured in modified Eagle's medium (MEM) 
supplemented with 10% FBS and 1% P/S at 37ºC and 5% CO2. Human aortic smooth 
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muscle cells (HASMCs) were cultured in DMEM supplemented with 1% P/S and smooth 
muscle growth supplement (SMGS). 
2.3.5 Immunofluorescent imaging and focal adhesion quantification 
 Hydrogels with Young's moduli of 18, 26, 165, and 400 kPa were made and 
subsequently coupled with 10 μg/cm2 collagen I. Cells were seeded at a density of 10,000 
cells/cm2 in serum-free medium and allowed to adhere for 48 hours.  Cells were rinsed 
two times with warm PBS, fixed with 4% formaldehyde, permeabilized with Tris-
buffered saline (TBS) containing 0.5% Triton X-100 (Promega), and blocked with AbDil 
(2 wt.% BSA in TBS with 0.1% Triton X-100, TBS-T). F-actin was labeled with Alexa 
Fluor 555-conjugated phalloidin for 1 h. Vinculin was labeled with a monoclonal mouse 
anti-vinculin antibody (Sigma-Aldrich) for 1 h, followed by an anti-mouse FITC 
secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h. 
Cell nuclei were labeled with DAPI (MP Biomedicals, Santa Ana, CA) for 5 min. Cells 
were thoroughly washed between labeling steps with TBS-T. Each sample was treated 
with ProLong Gold antifade reagent for 5 min before imaging on a Zeiss Axio Observer 
Z1 microscope with a 63x oil immersion objective (Carl Zeiss AG, Oberkochen, 
Germany), and images were compiled in ImageJ (NIH, Bethesda, MD). 
2.3.6 Quantification of protein adsorption 
 A modified ELISA [11] was used to  quantify non-specific protein adsorption. 
The fully swollen hydrogels were incubated with 10 mg/mL bovine serum albumin 
(BSA; Sigma) for 20 h at 37 °C. The gels were subsequently incubated with a primary 
antibody to BSA (Life Technologies) and a secondary antibody conjugated to horseradish 
peroxidase (HRP; Abcam, Cambridge, U.K.) in PBS for 90 min. The gels were washed 5 
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times with PBS between each incubation. The gels were then incubated with 0.1 mg/mL 
3,3′,5,5′-tetramethylbenzidine (TMB; Sigma) and 0.06% hydrogen peroxide (Fisher) in 
0.1 M sodium acetate (pH 5.5; Sigma) for 1 h at room temperature with shaking. Then an 
equal volume of 1 M sulfuric acid (Sigma) was added, and the absorbance at 450 nm was 
measured with a ELx800 absorbance microplate reader (BioTek). 
2.3.7 Statistical Analysis 
 Statistical analysis was performed using Prism v5.04 (GraphPad Software, La 
Jolla, CA). Statistical significance was evaluated by either using unpaired Student’s t 
tests (with Welch’s correction as necessary) or one-way analysis of variance (ANOVA) 
with a Tukey post-test. Data are reported as mean ± standard deviation. p ≤ 0.05 is 
denoted with *, ≤ 0.01 with **, and ≤ 0.001 with ***; P > 0.05 is considered not 
significant (“ns”).  
2.4 Results 
2.4.1 PEG-PC hydrogels have a wide range of Young's Moduli 
 PEG-PC hydrogels were synthesized by combining various concentration of 
PEGDMA with 0.6M PC (17 wt %) followed by free-radical polymerization (Figure 2.1). 
The photopolymerized PEG-PC hydrogels have a tunable mechanical range over 4 orders 
of magnitude of Young's moduli, from 0.9 ± 0.2 kPa at 7.4 mM (0.5 wt %) PEGDMA to 
9300 ± 900 kPa at 0.7 M (55 wt %) PEGDMA (Figure 2.2).  
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Figure 2.1 Schematic of PEG-PC hydrogel structure. PEG-PC hydrogels were 
prepared by addition of PEGDMA and PC followed by free-radical polymerization. At 
low PEGDMA concentrations, the network structure is dominated by PEGDMA-cross-
linked linear PC polymers, whereas the network structure is dominated by PEGDMA 
with  sparsely distributed PC groups at very high PEGDMA concentrations. Figure 
adapted with permission from [9]. © 2013 American Chemical Society. 
 
 When APS and TEMED are used as initiators for polymerization, there were 
minor differences in Young's modulus compared to using Irgacure for the same 
PEGDMA concentration (Figure 2.3A). This trend was consistent at low concentrations 
of PEGDMA. When comparing the gel fractions between the two polymerization 
methods, polymerizing with Irgacure is less efficient, and the resulting gels had larger 
mesh sizes and were softer (Figure 2.3B). 
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Figure 2.2 Young's modulus of PEG-PC. Young’s modulus, E, of PEG-PC hydrogels 
as a function of PEG cross-linker concentration from 7.4 mM to 0.7 M. PC was held at 17 
wt % (0.6 M). Error bars are standard deviations. Each adjacent pair is significantly 
different as determined by an unpaired Student’s t test with p < 0.001 or better. Figure 
adapted with permission from [9]. © 2013 American Chemical Society. 
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Figure 2.3 The mesh sizes and Young's modulus of PEG-PC following 
polymerization with Irgacure and APS/TEMED. The mesh sizes and Young's 
modulus varies between two different methods of polymerization, Irgarcure and 
APS/TEMED, at low PEGDMA concentrations. (A) Young's modulus of hydrogels 
polymerized with APS/TEMED are much higher compared to polymerization with 
Irgacure at low PEGDMA concentrations. (B) Hydrogels polymerized with APS/TEMED 
have smaller mesh sizes and higher percentage of polymerization. Figure adapted with 
permission from [9]. © 2013 American Chemical Society. 
A 
B 
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2.4.2 PEG-PC have small mesh sizes and structural dependent swelling 
 When the amount of PEGDMA cross-linker increases from 7.4 mM to 0.7 M, the 
mesh size decreases from 5.3 ± 0.4 nm to 0.95 ± 0.01 nm (Figure 2.4). However, the 
expected strong correlation between mesh size and Young’s modulus was found only 
over a partial range of cross-linker concentrations: from 7.4 to 135 mM PEGDMA 
(Pearson’s R = −0.8383, p < 0.05) and from 0.3 to 0.7 M PEGDMA (Pearson’s R = 
−0.9572, p < 0.05). Interestingly, these behaviors separate where the weight percent of 
PC and PEGDMA are equal in the gel. This finding suggests a hydrogel structural 
change, from one dominated by methacrylic PC polymer that is cross-linked by 
PEGDMA to one dominated by a PEG polymer, which is also cross-linked by PEGDMA, 
with PC pendant groups (Figure 2.1). The percentage of PBS uptake was calculated from 
the masses of the fully swollen hydrogels and pre-swelling hydrogels (right after 
polymerization). Due to the hydrophilicity of the PC groups, PEG-PC can  swell in PBS 
at all cross-linker concentrations, and there are also two different swelling regimes that 
are separated at the point where the hydrogel structural change occurs (Figure 2.5).   
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Figure 2.4 The average mesh sizes of PEG-PC hydrogels (PC at 0.6 M) as a function 
of PEG cross-linker concentration. Error bars are standard deviations (N ≥ 4). Figure 
adapted with permission from [9]. © 2013 American Chemical Society. 
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Figure 2.5 PEG-PC swelling behavior. PEG-PC swelling behavior in PBS, which is 
maintained at even very high cross-linker concentrations. Figure adapted with permission 
from [9]. © 2013 American Chemical Society. 
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2.4.3 PC groups reduce non-specific adsorption of proteins to PEG gel 
 Collagen I, which was covalently coupled to the hydrogel surface by using sulfo-
SANPAH, was detected by immunofluorescence, whereas no collagen I was detected on 
gel surfaces without the use of sulfo-SANPAH (Figure 2.6). These results demonstrate 
qualitatively that PEG-PC hydrogels are non-fouling to protein adsorption. To determine 
quantitatively whether incorporation of the hydrophilic PC groups enhanced resistance to 
protein adsorption to PEGDMA, bovine serum albumin (BSA) was allowed to adsorb to 
the surface of PEGDMA only (0.145 M) and PEG-PC (0.6 M PC and 0.054 M 
PEGDMA) hydrogels that had the same Young's modulus, and an ELISA was performed. 
There was a small amount of BSA detected on PEGDMA hydrogel surface, but not with 
the PEG-PC hydrogel (Figure 2.7A). When the PEGDMA concentration was kept 
constant at 0.084 M whereas PC was varied from 0.15 to 0.6 M, the BSA adsorption 
decreased with increasing PC content (Figure 2.7B). 
      With sulfo-SANPAH            Without sulfo-SANPAH 
  
Figure 2.6 Proteins can be coupled to PEG-PC surface in a controllable manner. 
Collagen I is covalently coupled to the gel surface by using sulfo-SANPAH.  
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Figure 2.7 PEG-PC hydrogels are non-fouling. (A) No BSA was detected on the PEG-
PC hydrogels compared to PEGDMA hydrogels that have similar modulus. (B) Adsorbed 
BSA at a constant PEGDMA concentration decreases with increasing PC content, 
demonstrating the ability of PC to prevent fouling. Figure adapted with permission from 
[9]. © 2013 American Chemical Society. 
 
2.4.4 PEG-PC hydrogels are suitable for mechanobiology studying of various cell 
types 
 PEG-PC hydrogels were polymerized and covalently attached on glass coverslips. 
Integrin-binding ECM proteins were covalently coupled to the hydrogel surface in order 
to induce cell adhesion and spreading (Figure 2.8). The two methods used to couple ECM 
proteins were sulfo-SANPAH and PEG-SVA (Figure 2.9). When neither of the 
heterobifunctional cross-linker was used, a minimal cell attachment and spreading was 
observed as indicated in Figure 2.9A with HASMCs (bottom left) and HEP3Bs (bottom 
right). This result demonstrates that PEG-PC hydrogels are non-fouling, resistant to non-
specific cell attachment, and useful for studies in which parsing the roles of integrin-
binding versus mechanical properties is desired. Many different cell types can also attach 
and spread out on PEG-PC gels with different stiffnesses (Figure 2.10). 
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Figure 2.8 Schematic of cell attachment to PEG-PC hydrogel via integrin binding. 
 
 
Figure 2.9 Cell adhesion can be controlled through protein coupling. (Left) HASMCs 
on PEG-PC (170 kPa) with (top) or without (bottom) sulfo-SANPAH and collagen I at 10 
μg/cm2; scale bar is 100 μm. (Right) HEP3B cells on PEG-PC (8.3 kPa) with (top) or 
without (bottom) PEG-succinimidyl valerate (PEG-SVA) and 65% collagen III, 23% 
collagen I, and 2% fibronectin at 5 μg/cm2; scale bar is 200 μm. Figure adapted with 
permission from [9]. © 2013 American Chemical Society. 
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Figure 2.10 Modulus and integrin-binding on PEG-PC gels controls cell morphology. (i, ii) HASMCs on PEG-PC (compliant = 3 
and stiff = 170 kPa, respectively, except for SkBr3 for which stiff = 400 kPa) with collagen I. Vinculin = green, F-actin = red, and 
Nucleus = blue. (iii, iv) HEP3Bs. (v, vi) MDA-MB-231s. (vii, viii) SkBr3s. Scale bar is 20 μm. Figure adapted with permission from 
[9]. © 2013 American Chemical Society. 
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Figure 2.11 Image thresholding and focal adhesion tracing. Image thresholding and 
focal adhesion tracing (labeled vinculin) were performed in ImageJ. Figure adapted with 
permission from [9]. © 2013 American Chemical Society. 
 
 In order to demonstrate that cells sense differences in the stiffness of PEG-PC 
hydrogels, the number of focal adhesions, their areas, and shapes were quantified. Liver 
cancer (HEP3B) and two breast cancer cell lines (SkBr3 and MDA-MB-231) were 
cultured for 48 h on PEG-PC gels of varying stiffness, coupled with 10 μg/cm2 collagen 
I. The cells were then fixed and stained for vinculin, which co-localizes with focal 
adhesions. ImageJ was used to quantify the focal adhesions (Figure 2.11). HEP3Bs had 
significantly fewer focal adhesions per cell on the 165 and 400 kPa gels compared the 18 
kPa gels, whereas the amount of focal adhesions of the other cell lines did not show any 
significant difference with respect to stiffness (Figure 2.12A). Focal adhesion area 
decreased with Young’s modulus in SkBr3 and 231 cells (areas on the stiffest PEG-PC 
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were reduced approximately 37% and 45% from the softer PEG-PC hydrogels, p < 0.05 
and p < 0.01, respectively), and interestingly, HEP3B focal adhesion area is biphasic 
(area on 26 kPa PEG-PC is 65% larger than on 18 and 165 kPa, p < 0.01) (Figure 2.12B). 
SkBr3 was the only cell line that had focal adhesion elongation decreases with increasing 
stiffness (Figure 2.12C). These results demonstrate the ability of PEG-PC hydrogel 
mechanical properties to tune cytoskeletal organization and reveal that 
mechanosensitivity is cell line specific. The proliferation of these cell lines on the same 
stiffnesses and the Spearman correlation between the proliferation and focal adhesion 
were also quantified. There was not any correlation between proliferation and focal 
adhesion area or elongation (Figure 2.13).  
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Figure 2.12 Focal adhesion characterization. PEG-PC modulus control of focal 
adhesions is cell-specific. Average number of focal adhesions (FA) counted per cell (A), 
average focal adhesion area (B), and average focal adhesion elongation (C) as a function 
of PEG-PC modulus. Figure adapted with permission from [9]. © 2013 American 
Chemical Society. 
 
  
A 
B C 
 57 
 
SkBr3
0.0 0.5 1.0 1.5
0.0
0.5
1.0
1.5
2.0
2.5
Proliferation
FA
 A
re
a 
( µ
m
2 )
SkBr3
0.0 0.5 1.0 1.5
0
2
4
6
8
Proliferation
FA
 E
lo
ng
at
io
n
 
HEP3B
0 1 2 3 4
0.0
0.5
1.0
1.5
2.0
2.5
Proliferation
FA
 A
re
a 
( µ
m
2 )
HEP3B
0 1 2 3 4
0
2
4
6
8
Proliferation
FA
 E
lo
ng
at
io
n
 
MDA-MB-231
0.0 0.5 1.0 1.5 2.0 2.5
0.0
0.5
1.0
1.5
Proliferation
FA
 A
re
a 
( µ
m
2 )
MDA-MB-231
0.0 0.5 1.0 1.5 2.0 2.5
0
1
2
3
4
5
Proliferation
FA
 E
lo
ng
at
io
n
 
Figure 2.13 Correlation between focal adhesion and proliferation. There is not any 
correlation between proliferation and area or shape of focal adhesions. Correlation 
between proliferation and focal adhesion area of (A) SkBr3, (C) HEP3B, (E) MDA-MB-
231. Correlation between proliferation and focal adhesion elongation of (B) SkBr3, (D) 
HEP3B, (F) MDA-MB-231.  
A 
C D 
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2.5 Discussion 
 With 17 wt % (0.6 M) of PC, polymerization of PEG-PC hydrogels can be 
achieved with the amount of PEGDMA cross-linker as low as 7.4 mM, which results in 
0.9 kpa hydrogels, and the hydrogel stiffness can be expanded up to 9,300 kPa at 0.7 M 
of PEGDMA (Figure 2.14). PEG-PC hydrogels can also be polymerized with lower 
concentrations of PC combined with higher concentrations of  PEGDMA such as with 
13.5 wt % PC (Figure 2.15) and 8 wt % PC (Figure 2.16). However, the hydrogels only 
remain transparent with an addition of PEGDMA cross-linker up to 0.3 M, whereas 
PEGDMA only hydrogels are opaque at low PEGDMA and become more transparent as 
the cross-linker concentration increases (Figure 2.17).  
 
 
Figure 2.14 Young's modulus of PEG-PC. Increasing the PEGDMA also increases the 
Young's Modulus. The PC content was held at 17 wt. % (0.6 M). Figure adapted with 
permission from [9]. © 2013 American Chemical Society. 
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Figure 2.15 Young's modulus of PEG-PC at 0.5 M PC. Young’s modulus, E, of PEG-
PC hydrogels as a function of PEG cross-linker concentration from 108 mM to 133 mM. 
PC was held at 13.5 wt. % (0.5 M). Error bars are standard deviations. 
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Figure 2.16 Young's modulus of PEG-PC at 0.3 M PC. Young’s modulus, E, of PEG-
PC hydrogels as a function of PEG cross-linker concentration from 83 mM to 179 mM. 
PC was held at 7.6 wt. % (0.3 M). Error bars are standard deviations. 
 
 
 
 
Figure 2.17 Images of PEG-PC hydrogels. PEG-PC hydrogels are optically transparent 
at low PEGDMA concentrations. The concentrations shown are of PEGDMA. PEG-PC 
hydrogels are 0.6 M PC. Figure adapted with permission from [9]. © 2013 American 
Chemical Society. 
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 The range of stiffness of PEG-PC hydrogels is much wider than PEGDMA only 
hydrogels, and it covers the stiffness of many tissue types such as liver (5-55 kPa) [12–
14], breast tumors (134-166 kPa) [15], articular cartilage (950 kPa), spinal cord (89 kPa), 
thyroid (9 kPa) [16].  PEGDMA  hydrogels cannot polymerize at concentrations less than 
70 mM (5 wt %), limiting the range of moduli obtainable. Incorporation of the PC 
polymer allows polymerization with as low as 7.4 mM PEGDMA (0.5wt %). This is 
likely due to the overall increase in polymer mass contributed from the PC. The 135 mM 
cross-linker hydrogels had mesh sizes half that of a 135 mM PEGDMA gel without PC, 
whereas the Young’s modulus is nearly 10 times higher [17], implying the inherent 
structural changes when PC is incorporated. At concentrations of PEGDMA above 135 
mM, there was a regime change within the hydrogel from a PC-domintated structure to a 
PEG-dominated structure. The changes in Young's modulus and mesh size are less 
dependent on cross-linker concentration as opposed to lower PEGDMA regime. 
However, the swelling behavior in this regime is still largely dependent on PEGDMA 
concentrations. Overall, the ability of PEG-PC to form two very different polymer 
structures may explain for its impressive mechanical range. 
 PEG-PC hydrogels allow independent tunability of stiffness and ligand density 
and have enhanced hydrophilicity for reduction of nonspecific protein adsorption while 
maintaining high optical clarity for modern quantitative microscopy techniques. PEG is a 
well characterized amphiphilic polymer, and PEG-based hydrogels are widely used in 
many biological applications due to its biocompatibility. PC molecules contain 
phospholipid groups, which are major components of biological membrane. Thus, 
combining PC and PEG to make PEG-PC results in highly biocompatible hydrogels. In 
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their studies, Ishihara et al. suggests that the state of water molecule around PC polymers 
is different from that of general amphiphilic polymers [7]. PC-incorporated polymers 
have large amount of free water in hydrated state, which is similar to the state water in 
aqueous solution. Thus, when a protein molecule in aqueous solution is in contact with 
the polymer surface, it does not need to release bound water molecules. This phenomena 
prevents the hyrophobic interactions between the protein molecule and the hydrophobic 
part of the polymer, which is a mechanism for protein adsorption. Protein molecules can 
contact PC-incorporated polymers reversibly without going through an irreversible 
conformational change in structure, which allows exposure of hydrophobic domains, 
leading to hydrophobic interactions [7]. This unique property of the PC groups imparts a 
highly anti-protein adsorption characteristic to PEG-PC hydrogels. Furthermore, PEG-PC 
hydrogels were experimentally shown to be more resistant to BSA adsorption compared 
to PEGDMA hydrogels of the same modulus, and the amount of adsorbed protein is 
inversely related to the PC content of the hydrogel (Figure 2.7). These results further 
confirm the non-fouling properties of PC. Another hydrophilic hydrogel system widely 
used is derived from hyaluronic acid [18–20]. However, hyaluronic acid can have 
bioactivity through interaction with CD44 receptors in certain cell types [18,20]. Thus, 
PC has the advantage of being biocompatible without interfering with cell behavior.  
 When HASMC, HEP3B, SkBr3, and MDA-MB-231 cell lines were cultured on 
PEG-PC gels from 18 to 400 kPa Young's moduli functionalized with collagen I, their 
focal adhesion properties corresponding to substrate modulus were cell-type dependent. 
These cell types originate from tissues that have different stiffnesses; thus their stiffness 
sensing  can be different among cell type. Besides, the mechanotransduction machinery 
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depends on many factors such as integrins, proteins that make up adhesion complexes, 
proteins that regulate actin assembly at adhesion sites, and many more. For example, β1 
integrin is a major integrin that binds to collagen I [21], and SkBr3 cells inherently have 
lower β1 intergin expression compared to MDA-MB-231 [22]. This partially helps to 
explain some observed differences in their focal adhesion properties between these two 
cell lines.  
2.6 Conclusions 
 A new biomaterial platform, PEG-PC, was developed through copolymerization 
of PEGDMA polymers and PC monomers. This novel biomaterial has a much wider 
range of Young's modulus and more anti-adsorptive to non-specific protein bindings than 
PEGDMA hydrogels. Its impressive mechanical properties, which can be tuned over four 
orders of magnitude in Young's modulus, make it an ideal platform for 
mechanotransduction studies. It was demonstrated that different cell types can be cultured 
on PEG-PC surfaces and can sense different stiffnesses. In addition, PEG-PC is 
inexpensive and easy to synthesize, and these advantages will make it feasible for other 
labs to apply this system in their studies of cellular responses to ECM modulus.    
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CHAPTER 3 
 
THE ROLE OF THE EXTRACELLULAR MATRIX CUES IN CELL 
PROLIFERATION AND DRUG RESPONSE 
 
3.1 Abstract 
 The tissue ECM has a crucial role  in modulating the normal function of many 
cell types in the tissue, and deregulation of this matrix can cause different types of 
disease including cancers. The change from a normal ECM, which is the basement 
membrane ECM, to the cancerous ECM, which is rich in fibrillar collagens, induced 
some breast and liver cancer cells to be more resistant to sorafenib, and this trend is cell-
type dependent. The proliferation of many cancer cell lines was regulated by the substrate 
modulus; however, the trend of proliferation with modulus also depends on the cell type. 
High-throughput platforms were developed from different types of hydrogels such as 
PAA, PEG, and PEG-PC. These platforms can be coupled with various types of ECM 
protein or cocktail of ECM protein. These platforms can allow multiple drugs to be tested 
with many cells on various moduli and proteins that capture the physicochemical 
properties of the tissue ECM.  
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3.2 Introduction 
  In drug development, multiple compounds are tested in plastic multi-well plates, 
followed by preclinical and clinical trials. This process costs over one billion dollars, and 
takes 11 to 15 years per drug on average [1].  The cost burden is partially caused by 
inefficiencies in high-throughput screening, as small molecule candidates often show 
efficacy in cells on plastic plates, but fail in animal or human trials. In order to improve 
high-throughput screening, compounds should be tested in cells on biomaterial platforms 
that have the ability to capture tissue properties. Traditionally, the cell-based high-
throughput screening is usually done with cells plated on multi-well plastic plates such as 
96- or 384- well plates. These plastic plates lack relevant chemical and physical cues, 
which are found in the ECM of native tissues. The tissue ECM is much softer than plastic 
plates, and it contains many growth factors and proteins that drive the cell biological 
functions through binding to cellular growth factor receptors and integrins [2,3]. Often, 
disruption in ECM homeostasis will lead to disorganized and deregulated ECM, resulting 
in cancer development and growth [2,4,5]. Hence, it is necessary to develop a new drug 
testing platform that not only includes human cell lines and appropriate growth factors 
but also allows a precise control over integrin-binding and substrate stiffness.  Many 
groups are spurring the development of novel cell culture platforms for more rational and 
predictive drug discovery  [6–8]; however, I found that existing systems are either 
cumbersome to use, or have limited adaptability. In response, I adapted the novel PEG-
PC hydrogel system, an easy to use biomaterial, which is optically transparent, forms gels 
ranging from 1-10,000 kPa in Young's modulus, can be coupled with any protein or 
peptide of interest, and rapidly polymerizes within 96-well plates [9]. This novel platform 
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allowed me to quantify drug response in a high-throughput manner across a range of 
stiffness and integrin-binding conditions. 
3.3 Materials And Methods 
3.3.1 Cell culture 
 All supplies were purchased from Life Technologies (Carlsbad, CA) unless 
otherwise noted. Human breast cancer cell lines (MDA-MB-231, BT549, MCF7 and 
SkBr3) were generous gifts from Dr. Shannon Hughes at the Massachusetts Institute of 
Technology, and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) 
at 37ºC and 5% CO2.  Human hepatocellular carcinoma (HCC) cells (HEP3Bs, American 
Type Culture Collection, Manassas, VA) were cultured in modified Eagle's medium 
(MEM) supplemented with 10% FBS and 1% P/S at 37ºC and 5% CO2. Human breast 
cancer cell lines HCC38 and AU565 were generous gifts from Dr. Mario Niepel at the 
Harvard University, and they were cultured in Roswell Park Memorial Institute (RPMI) 
medium supplemented with 10% FBS and 1% P/S at 37ºC and 5% CO2. 
3.3.2 Protein coating and drug treatment on 96-well tissue culture plates 
 Sterile fibronectin protein solutions at different concentrations (0.5, 2.5, 5, 10 
μg/cm2) were made by mixing human plasma fibronectin (EMD Millipore, Billerica, 
MA) in a buffer solution (pH ~ 9.4 with acetic acid) that contains sodium carbonate 
(Thermo Fisher Scientific, Waltham, MA)  and sodium bicarbonate (Thermo Fisher 
Scientific) at 15 mM and 35 mM, respectively. 100 μL of the fibronectin solution were 
added to each well of 96-well plates, and the plates were incubated overnight at 4ºC. 
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After incubation, the plates were washed 3 times with sterile phosphate buffered saline 
(PBS) and then incubated with sterile 10 mg/mL of pluronic F127 (Sigma-Aldrich, St. 
Louis, MO) dissolved in PBS. After a day of pluronic blocking at 4ºC, the plates were 
washed 3 times with sterile PBS, and 10,000 cells/well were seeded in serum-free 
medium. After 24 h, the medium was replaced with serum-free medium supplemented 
with 20 ng/mL of platelet-derived growth factor (PDGF-BB, eBioscience, San Diego, 
CA) and 20 ng/mL of epidermal growth factor (EGF, R&D Systems, Minneapolis, MN). 
After 24 h, cells were treated with sorafenib (LC Laboratories, Woburn, MA) from 0 to 
30 μM, diluted in growth factor supplemented serum-free medium. After 24 h, cell 
proliferation was quantified with CellTiter 96 AQueous One Solution Cell Proliferation 
Assay (Promega, Madison, WI) (20 μL of assay per well and 4 hour incubation) and read 
at 490 nm (BioTek ELx800 microplate reader, BioTek, Winooski, VT). Cell apoptosis 
was quantified with propidium iodine (Life Technologies). When the propidium iodide 
was used, the medium in each well was aspirated and replaced with 200 μL of 4.5 μM 
propidium iodide in PBS. After 30 minute incubation at 37ºC, the plate was read at 
530/620 nm wavelength (emission/excitation) with a fluorescent plate reader 
(Spectramax, Molecular Devices, Sunnyvale, CA). The inhibitory concentration at 50% 
(IC-50) was calculated with Prism v5.04 (GraphPad Software, La Jolla, CA). 
 For the collagen-rich ECM coating, the protein cocktail (5 μg/cm2 total) was 
comprised of 65% type I collagen (rat tail, Life Technologies), 33% type III collagen 
(FibroGen, San Francisco, CA), and 2% fibronectin. The plates were incubated with both 
collagen I and III mixed in 0.02 M acetic acid for a day and then with fibronectin in 
sodium carbonate/bicarbonate buffer for another day before blocking with pluronic F127. 
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The plates were kept at 4ºC during the incubations and washed 3 times with PBS between 
each incubation. For the basement membrane ECM, the protein cocktail (0.5 μg/cm2 
total) was comprised of 46% collagen IV (Neuromics, Edina, MN), 46% fibronectin and 
8% mouse laminin (Life Technologies). The procedure is similar to collagen-rich ECM 
coating with the exception that the plate was incubated with collagen IV in 0.02 M acetic 
acid for a day before incubating fibronectin and laminin mixed in sodium 
carbonate/bicarbonate buffer for another day. After blocking with pluronnic F127, the 
cell seeding and sorafenib treatment were similar to that described above. 
3.3.3 Quantification of cell adhesion 
 HEP3B cells were seeded on a collagen-rich and basement membrane ECM-
coated 96-well plate. After 24 h of adhesion, cells were washed with warm PBS, and 50 
μL of 0.5 % (wt./v.) crystal violet (Thermo Fisher Scientific) in 20% (v./v.) methanol in 
water were added to each well. The plate was incubated for 10 min at room temperature. 
Then the plate was washed twice with PBS, and 100 uL of 1% (wt./v.) sodium dodecyl 
sulfate (SDS) in water was added to solubilize the stain. The plate was shaken on a plate 
shaker until all stains were dissolved, and then the absorbance was read at 570 nm on a 
plate reader (BioTek). 
3.3.4 Real-time quantification of Caspase 7 activity 
 The plasmids that were used for expression of caspase-activable green fluorescent 
protein (CA-GFP) were a generous gift from Dr. Jeanne Hardy (Department of 
Chemistry, University of Massachusetts Amherst). The plasmids were inserted into E. 
Coli bacteria in a cuvette through electroporation with the Gene Pulser Xcell™ system 
(Bio-Rad Laboratories, Hercules, CA). After electroporation, 100 μL of Super Optimal 
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Broth (SOC) was added immediately into the cuvette, and the cuvette was incubated at 
37ºC for 1 h. After incubation, 1 μL of bacterial solution was mixed with 99 μL of SOC 
medium, and the mixture was spread evenly on an agar plate. The agar plate was made 
with 1.5% wt./v. agar in Lysogeny Broth (LB) supplemented with 0.1 mg/mL ampicillin 
(Thermo Fisher Scientific) (prepared at 500x or 50 mg/mL in water). The plate was 
incubated at 37ºC for 16-20 h. After incubation, a colony was picked and incubated with 
3 mL of LB medium, which is supplemented with 0.1 mg/mL ampicillin, for 16-20 h at 
37ºC with shaking at 225 rpm. The plasmids were then purified using Pureyield™ 
Plasmid Miniprep System (Promega) following the manufacturer's protocol. The plasmid 
concentrations were determined with the NanoDrop (Thermo Fisher Scientific). 
 HEP3B cells were allowed to adhere to a 24 well plate. The cells were transfected 
with 1,000 ng of plasmid per well using Lipofectamine reagent (Life Technologies) 
following the manufacturer's protocol. Briefly, the plasmids were diluted in 100 μL Opti-
Mem (Life Technologies). 0.5 μL of PLUS reagent was added into the mixture, and it 
was incubated for 15 min at room temperature. During the incubation, the cells were 
washed with Opti-MEM, and the medium was replaced with Opti-MEM. After a 15 min 
incubation, 2 μL of Lipofectamine reagent was added to the plasmid complex mixture, 
and the mixture was incubated for 25 min before being transferred to the well. After 5 h, 
the cells were washed and replaced with medium containing 10% FBS only. After 24 h, 
the cells were detached and seeded onto a glass-bottom 24-well plate (Mat Tek, Ashland, 
MA) coated with either collagen-rich or basement membrane ECM. After 24 h, the cells 
were treated with 4 μM sorafenib, and live-cell imaging was performed with a Zeiss Axio 
Observer Z1 microscope with a 63x oil immersion objective (Carl Zeiss AG, 
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Oberkochen, Germany). Images were analyzed in ImageJ (NIH, Bethesda, MD). The 
corrected total cell fluorescence (CTCF) was calculated from the following equation: 
 CTCF = Integrated Density - (area of selected cell x mean fluorescence of 
background readings) 
3.3.5 96-well hydrogel platform 
Glass-bottom 96-well plates (no. 1.5 coverslip glass; In Vitro Scientific, 
Sunnyvale, CA) were plasma treated (Harrick Plasma, Ithaca, NY) and subsequently 
methacrylate-silanized with 2 vol% 3-(trimethoxysilyl) propyl methacrylate (Sigma-
Aldrich, St. Louis, MO) in 95% ethanol (adjusted to pH 5.0 with glacial acetic acid) for 5 
min, washed 3 times with 100% ethanol, and dried at 40 °C for 30 min.  
To make PEG-PC hydrogels, PEGDMA (Mn 750, Sigma-Aldrich), from 0.6-9.1 
wt%, was combined with 17 wt% 2-methacryloyloxyethyl phosphorylcholine (PC) 
(Sigma-Aldrich) in phosphate buffered saline (PBS). These PEGDMA crosslinker 
concentrations tune the Young's moduli of the resulting gels from 6 to 400 kPa [9]. 
Solutions were sterilized using a 0.2 μm syringe filter (Thermo Fisher Scientific) and 
degassed by nitrogen sparging for 30s. Free-radical polymerization was induced by 
addition of 0.05 wt% ammonium persulfate (APS) and 0.125 vol% 
tetramethylethylenediamine (TEMED, Bio-Rad Laboratories). Hydrogels of 40 μL per 
well in the 96-well plates were polymerized under nitrogen for 10 min.  
To make polyacryamide (PAA) hydrogels, acrylamide (40 wt % acrylamide 
solution) (A) and N, N'-methylenediacrylamide (2% bis solution) (B) are mixed together 
at different wt. % in 1X phosphate buffered saline (PBS, pH 7.0) in order to create 
hydrogels with various stiffnesses. Specifically, the combinations of 5%A/0.1%B, 
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8%A/0.2%B, 8%A/0.4%B, 8%A/0.6%B, 15%A/1.2%B (v./v.) create hydrogels that have 
these stiffnesses: 1, 22, 46, 52, and 308 kPa, respectively [10]. Solutions were sterile-
filtered and degassed by nitrogen sparging. To induce polymerization in the 96-well 
plates, APS and TEMED were used at 0.02 wt% and 0.05 vol%, respectively.  
To make PEG hydrogels, PEGDMA was mixed with PBS at different 
concentrations: 10, 15, 20, 25, 30 vol%. Solutions were sterile-filtered and degassed by 
nitrogen sparging. APS and TEMED were used at 0.1 wt% and 0.25 vol%, respectively. 
 Post-polymerization, hydrogels were allowed to swell for 24 h in PBS, then 
treated with 100 μL of sulfo-SANPAH (ProteoChem, Denver, CO; 0.6 mg/mL in pH 8.5 
HEPES buffer) under UV light for 20 min, rinsed twice with HEPES buffer, and followed 
immediately by incubation with protein mixtures overnight. ECM protein mixtures 
defined as “bone” composed of 65% rat tail collagen I and 1% osteopontin (R&D 
Systems) at 5 μg/cm2, "brain" composed of 50% fibronectin, 25% vitronectin (R&D 
Systems), 20% tenascin C (R&D Systems), and 5% mouse laminin at 1 μg/cm2, or "lung" 
composed of 33% mouse laminin, 33% collagen IV, 15% collagen I, 15% fibronectin, 
4% tenascin C at 2 μg/cm2. When only collagen I was used, the concentration was 10 
μg/cm2. All proteins were mixed in pH 3.8 PBS. Post-protein coupling, the gels were 
rinsed twice with PBS, UV-sterilized for 1 h, and rinsed with sterile medium before cell 
seeding.   
3.3.6 Proliferation of breast cancer cells 
 For the proliferation experiments on PEG-PC coupled with collagen I, SkBr3 and 
MDA-MB-231cells were seeded at 6,000 cells/well in serum-free DMEM with 1% P/S. 
HEP3B cells were seeded at 6,000 cells/well in MEM media with 10% FBS and 1% P/S. 
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After 24 h, the media was changed to 10% FBS media. Media was replenished every 2 
days. Five days after seeding, the proliferation was measured with the CellTiter96 assay 
as described above. 
 For the proliferation experiments on PAA and PEG gels coupled with collagen I, 
231s were seeded at 10,000 cells/well in DMEM with 10% FBS and 1% P/S. The 
proliferation was measured 2 days after seeding. 
 For the proliferation experiments on PEG-PC gels coupled with either "bone", 
"brain", or "lung" proteins, 231s and MCF7s were seeded at 6,000 cells/well in DMEM 
with 10% FBS and 1% P/S; HCC38 and AU565 were seeded at 6,000 cells/well in RPMI 
with 10% FBS and 1% P/S. The proliferation was measured 7 days after seeding. 
3.3.7 Statistical Analysis 
 Statistical analysis was performed using Prism v5.04 (GraphPad Software, La 
Jolla, CA). Statistical significance was evaluated by either using unpaired Student’s t 
tests (with Welch’s correction as necessary) or one-way analysis of variance (ANOVA) 
with a Tukey post-test. Data are reported as mean ± standard deviation. p ≤ 0.05 is 
denoted with *, ≤ 0.01 with **, and ≤ 0.001 with ***; P > 0.05 is considered not 
significant (“ns”). 
3.4 Results 
3.4.1 The response of cancer cells to sorafenib depends on both ECM proteins and 
cell types  
 HEP3Bs were allowed to adhere to fibronectin coated on plastic plates at different 
protein concentrations and treated with sorafenib for 24 h. Both the IC-50s obtained from 
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the proliferation (Figure 3.1A) and apoptosis (Figure 3.1B) assays for sorafenib 
treatments indicate no significant difference across various protein concentrations. This 
result may suggest that the binding of HEP3Bs to fibronectin can be saturated at low 
protein concentration, and thus increasing the ligand density will not significantly alter 
HEP3Bs' responses to sorafenib. I also quantified the response of HEP3Bs to sorafenib in 
the presence of different protein cocktails that combined various proteins instead of just 
fibronectin. Similar to the results with fibronectin, the HEP3Bs' IC-50s were independent 
of protein concentration for both basement membrane ECM (collagen IV, laminin, and 
fibronectin) (Figure 3.2A) and collagen-rich ECM (collagen I, III, and fibronectin) 
(Figure 3.2B). Interestingly, the IC-50s on the collagen-rich ECM were higher than those 
on basement membrane ECM (4.6 vs. 3.1 μM). These results showed that the response of 
HEP3B to sorafenib is more dependent on the types of ligand binding than the ligand 
density. 
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Figure 3.1 Sorafenib IC-50s of HEP3B cells across different fibronectin 
concentrations. The inhibitory concentrations at 50% (IC-50s) of HEP3Bs are not 
significantly different across different fibronectin concentrations. (A) IC-50s were 
calculated from the proliferation measurements with the CellTiter96 assay. (B) IC-50s 
were calculated from the apoptosis measurement with the propidium iodide assay. 
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Figure 3.2 Sorafenib IC-50s of HEP3B cells across different protein mixture 
concentrations. The IC-50s of HEP3Bs are more dependent on protein types than protein 
concentrations. The IC-50s on (A) the basement membrane ECM (collagen IV, laminin, 
and fibronectin) are lower than those on (B) the collagen-rich (collagen I, III, and 
fibronectin), and the IC-50s on each ECM are similar across different concentrations. 
A 
B 
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 Motivated by the interesting observations above, I quantified the IC-50s of the 
other cell lines in response to sorafenib when placed on 5 μg/cm2 of collagen-rich ECM 
or 0.5 μg/cm2 of basement membrane ECM (Figure 3.3). The IC-50s of HEP3Bs, MDA-
MB-231s, and BT549s on collagen-rich ECM were 26%, 48%, and 54% higher than 
those on basement membrane ECM, respectively. However, the IC-50s of MCF7 and 
SkBr3 were not significantly different between the two ECMs. Therefore, the ability of 
cells to sense the differences in ECM binding was also cell type dependent. As a proof of 
concept, I used the crystal violet assay, which contains a DNA binding molecule, to 
quantify the HEP3B cell adhesion between the two ECMs. There was not any significant 
difference in the number of adherent cells between the collagen-rich and basement 
membrane ECMs (Figure 3.4). Thus, the difference in HEP3Bs' IC-50s between the two 
ECMs could not be caused by differences in cell adhesion.  
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Figure 3.3 Sorafenib IC-50s multiple cell types across different protein mixture 
concentrations. Most of cell lines are more resistant to sorafenib when adhering 
collagen-rich ECM. HEP3B, MDA-MB-231, and BT549 are sensitive to the change in 
ECM, whereas SkBr3 and MCF7 are not. 
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Figure 3.4 Adhesion quantification of HEP3B cells. The same amount of HEP3B cells 
adhere to both ECMs. Adhesion of HEP3Bs, which were quantified by crystal violet 24 h 
after cell seeding, is not significantly different between collagen-rich and basement 
membrane ECMs.  
 In addition, I quantified the response of HEP3B cells to sorafenib through the 
measurement of caspase-7 activity in real time. Caspase signaling plays an important role 
in regulating cellular apoptosis. Caspase-3/ -6/-7 are known to be the apoptosis 
executioners, which can cause cell shrinkage, membrane blebbing, and DNA 
fragmentation. These caspases can be activated by other upstream caspases such as 
caspase-2/-8/-9/-10 [11]. I transfected HEP3Bs with DNA plasmids that induced the 
expression of a green fluorescent protein (GFP).  The GFP activity is fully quenched by a 
short peptide that contains the caspase-7 recognition site DEVA [12]. When caspase-7 is 
activated, it will cleave the quenching peptide to release the GFP. Therefore, the amount 
of GFP detected is correlated to the amount of caspase activation. Images of the GFP 
activation were taken in real time after HEP3Bs were treated with 4 μM of sorafenib 
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(Figure 3.5). However, the CTCF, which was quantified by imageJ, did not show any 
difference between the two ECMs (Figure 3.6).  
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Figure 3.5 Expression of caspase-activable green fluorescent protein (CA-GFP) in 
HEP3B cells. HEP3Bs were transfected with plasmids that induced the expression of 
CA-GFP and allowed to adhere to the basement membrane ECM before treating with 
sorafenib. The GFP intensity keeps increasing over 24 hour under 4μM sorafenib 
treatment. Scale bar is 20 μm. 
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Figure 3.6 Fluorescent intensity of CA-GFP in HEP3B cells. The corrected total cell 
fluorescence increases over time and is similar between the two ECMs. 
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3.4.2 Substrate modulus affects cell proliferation 
 I adapted the PEG-PC, PAA, and PEG hydrogels into high-throughput platforms, 
which could be quickly used to study the relationship between mechanobiology and drug 
response. A representative image of  PEG-PC gels in a 96-well plate is shown in Figure 
3.7. The relationship between substrate modulus and cell proliferation was investigated 
with HEP3Bs, MDA-MB-231s, and SkBr3s. All cell lines were seeded on PEG-PC gels 
coupled with 10 μg/cm2 collagen I. Both MDA-MB-231 and HEP3B cells showed an 
increase in proliferation with increasing PEG-PC modulus (Figure 3.8A and B). HEP3Bs 
were the most stiffness-sensitive cell line. Its proliferation increased nearly 3 fold 
between 18 and 165 kPa gels, whereas 231s showed a 26% increase in proliferation 
between 18 and 26 kPa gels before leveling off at higher stiffnesses. SkBr3 proliferation 
decreased approximately 50% between the softest and stiffest gel conditions (Figure 
3.8C). MDA-MB-231s showed similar trends in increasing proliferation with increasing 
substrate modulus when placed on PAA gels (Figure 3.9) and PEG gels (Figure 3.10). 
While the proliferation on PAA gels showed a steady increase across the range of 
stiffness from 1 to 308 kPa, the proliferation trend on PEG-only gel was much more 
similar to PEG-PC gels with increasing proliferation at the lower stiffness range and 
saturating at higher stiffnesses (the modulus of 18.4% PEG-only gel was measured to be 
174 ± 9.8 kPa). 
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Figure 3.7 PEG-PC high-throughput platform. The high-throughput platform consists 
of a black-walled, glass bottom plate, with PEG-PC gels cast in each of the inner 6x10 
wells. 
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Figure 3.8 The proliferationof 231, HEP3B, and SkBr3 cells. The proliferation of (A) 
231, (B) HEP3B, and (C) SkBr3 cells on PEG-PC, which is coupled with collagen I, 
from 18 to 400 kPa was quantified 5 days post-seeding. Results are the fold changes 
relative to the softest condition (18 kPa). HEP3Bs' proliferation is strongly dependent on 
substrate modulus whereas the proliferations of 231s and SkBr3s are less sensitive to 
substrate modulus and display opposing trends. Figure adapted with permission from [9]. 
© 2013 American Chemical Society. 
A 
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Figure 3.9 The proliferation of 231 cells on PAA gels. The proliferation of 231 cells on 
PAA gels coupled with collagen I increases with increasing substrate modulus. The 
proliferation was quantified 2 day post-seeding. 
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Figure 3.10 The proliferation of 231 cells on PEG-only gels. The proliferation of 231 
cells on PEG-only gels coupled with collagen I increases with increasing PEGDMA 
concentrations at lower concentrations. The proliferation was quantified 2 day post-
seeding. 
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3.4.3 Proliferation can be regulated by both substrate modulus and ECM proteins 
 MDA-MB-231s, MCF7s, HCC38s, and AU565s were placed on 6, 23, and 400 
kPa PEG-PC gels that were coupled ECM proteins found in the brain (fibronectin, 
vitronectin, tenascin C, laminin), lung (laminin, collagen IV, collagen I, fibronectin, 
tenascin), and bone (collagen I and osteopontin). Both 231s and HCC38s proliferated 
more on lung and bone compared to brain, but there was not any significant difference 
between lung and bone (Figure 3.11A and B). However, AU565s were most proliferative 
on lung (Figure 3.11C), whereas MCF7s showed similar proliferation across the three 
different environments (Figure 3.11D). 
 
  
 91 
 
MDA-MB-231
Brain Lung Bone
0.0
0.5
1.0
1.5
2.0
2.5 **
***
Microenvironments
Pr
ol
ife
ra
tio
n 
(a
rb
. u
ni
t)
HCC38
Brain Lung Bone
0
1
2
3
4 **
***
Microenvironments
Pr
ol
ife
ra
tio
n 
(a
rb
. u
ni
t)
 
 
AU565
Brain Lung Bone
0
1
2
3 **
***
**
Microenvironments
Pr
ol
ife
ra
tio
n 
(a
rb
. u
ni
t)
MCF7
Brain Lung Bone
0
1
2
3
Microenvironments
Pr
ol
ife
ra
tio
n 
(a
rb
. u
ni
t)
 
Figure 3.11 The proliferation of many cell types across different 
microenvironments. The proliferation on different microenvironments is cell-type 
dependent. Both (A) 231s and (B) HCC38s show similar trends in proliferation and are 
more proliferative on lung and bone compare to brain microenvironment. (C) AU565s' 
proliferation is strongly dependent on types of microenvironments, whereas (D) MCF7s 
are not sensitive to the changes in microenvironments. 
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3.5 Discussion 
 The tumor microenvironment plays an important role in mediating signals for 
cancer cells to grow, resist chemotherapies, and metastasize to distal tissues [13–16]. 
Cancer cells can receive biochemical signals from the tumor microenvironment through 
growth factors released in the tumor tissue or binding of their integrins to ECM proteins. 
Integrins are heterodimers composed of an α- and  a β-subunits. Different 
heterodimerizations of α- and β-subunits are required when the cells bind to different 
types of ECM protein [17]. Binding of integrins to ECM proteins can mediate many 
different downstream signaling pathways such as PI3K/Akt and Ras/Raf/ERK to promote 
cell survival and proliferation or Rho/ROCK pathway to enhance cell motility [18], and 
integrin binding can also induce the drug resistance of cancer cells to other 
chemotherapeutic drugs [19]. Therefore, the switching of the basement membrane ECM, 
which is a representative of normal ECM [4], to the collagen-rich ECM, which is a 
representative of tumor ECM [4], can mediate resistance to sorafenib, which targets the 
Raf/ERK pathway [20]. The sorafenib resistance was observed in several cell lines such 
as HEP3Bs, 231s, and BT549s (Figure 3.3). Binding to collagen I was shown to mediate 
ERK signaling in T-Lymphocytes, whereas binding to laminin or fibronectin  did not 
sustain ERK activation [21]. Thus, the presence of relevance ECM binding proteins is 
necessary for cell-based drug screening. Integrin structure, expression and downstream 
signaling was found to be heterogeneous across breast cancer cell lines [22]. Perhaps, this 
could be an explanation for the heterogeneous responses among different cell types 
toward the changes in ECM proteins (HEP3B, MDA-MB-231, and BT549 vs. MCF7 and 
SkBr3) and the insensitivity of HEP3Bs toward the changes in protein concentration. 
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Although HEP3B cells seeded on collagen-rich were more resistant to sorafenib, the 
caspase-7 activation was similar between the two ECMs (Figure 3.6). The GFP was only 
activated after the cells were already dead and round, from 8 h to 24 h (Figure 3.5). There 
was not any change in GFP detected between 0.5 h and 8 h during the transition from 
being alive to being dead. These results can be indicative of non-caspase induced death 
mechanism in HEP3B liver cancer cells. In two other liver cancer cell lines, sorafenib 
was shown to induce cell death via caspase-3 activation in HEPG2, but not in PCL/PRF/5 
cells [20]. Sorafenib was also shown to induce apoptosis via nuclear translocation of 
apoptosis-inducing factor (AIF) in melanoma cells [23]. A few cells were found to have 
caspase-7 activated when sorafenib was added for just 0.5 h (cells in the bottom left 
corner of 0.5 h image, Figure 3.5). These cells could be dying via caspase-7 induced 
pathway due to natural causes before the addition of sorafenib since 0.5 h is too short for 
sorafenib to have any major effect. 
 As a proof of concept, cell proliferation was shown to be regulated by substrate 
modulus when cells were placed on PEG, PEG-PC, and PAA hydrogels coupled with 
collagen I (Figure 3.8, 3.9, 3.10). However, this modulus-regulated cell proliferation is 
cell-type dependent. Thus it is important to include relevant tissue modulus into the drug 
screening process since many drugs work by a mechanism of dampening cell 
proliferation. 
 When both substrate modulus and ECM proteins were varied, the substrate 
modulus and the ECM proteins synergistically regulate cell proliferation in certain cell 
type. MCF7 cell proliferation was insensitive to changes in microenvironments, and 
AU565 cells proliferated the most on the intermediate gel coupled with lung proteins 
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(Figure 3.11C). Thus, proliferation in this cell line is not a function of substrate modulus. 
Both MDA-MB-231 and HCC38 showed the similar proliferation trend as they 
proliferated the most on lung and bone gels. This could be due to the fact that lung and 
bone gels are stiffer than brain gels. 231s' proliferation saturated at gels that were stiffer 
than 26 kPa when they were seeded on collagen I (Figure 3.8A), and this trend is similar 
to the proliferation trend on brain (6 kPa), lung (23 kPa), and bone (400 kPa). This could 
infer that 231 proliferation is more strongly influenced by stiffness than the change in 
ECM proteins. Interesting, both 231s and HCC38s are triple negative, whereas AU565 
and MCF7 are HER2+ and luminal, respectively. Therefore, the relationship between cell 
proliferation and microenvironments could be subtype-dependent.  
3.6 Conclusions 
 I have shown that both ECM proteins and substrate modulus play an important 
role in regulating cell proliferation and response to drugs. The interactions between cells 
and these physicochemical cues are also dependent on cell types and subtype. Thus, both 
of these variables should be included in the cell-based high-throughput drug screening in 
order to bridge the gap between in vitro and in vivo models. The synthetic biomaterial 
platforms PEG-PC, PAA, and PEGDMA, which allow independent control of mechanical 
properties and ligand binding, were developed and proven to be useful for quantifying 
cell-matrix interactions in a high-throughput manner.  
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CHAPTER 4 
 
SORAFENIB RESISTANCE AND JNK SIGNALING IN CARCINOMA 
DURING EXTRACELLULAR MATRIX STIFFENING 
 
4.1 Abstract 
 Tumor progression is coincident with mechanochemical changes in the 
extracellular matrix (ECM). I hypothesized that tumor stroma stiffening, alongside a shift 
in the ECM composition from a basement membrane-like microenvironment toward a 
dense network of collagen-rich fibers during tumorigenesis, confers resistance to 
otherwise powerful chemotherapeutics. To test this hypothesis, I applied the high-
throughput drug screening PEG-PC platform that I created as described in Chapter 3, and 
customized it to capture the stiffness and integrin-binding profile of in vivo tumors. I 
report that the efficacy of a Raf kinase inhibitor, sorafenib, is reduced on stiff, collagen-
rich microenvironments, independent of ROCK activity. Instead, sustained activation of 
JNK mediated this resistance, and combining a JNK inhibitor with sorafenib eliminated 
stiffness-mediated resistance in triple negative breast cancer cells. Surprisingly, neither 
ERK nor p38 appears to mediate sorafenib resistance, and instead, either ERK or p38 
inhibition rescued sorafenib resistance during JNK inhibition, suggesting negative 
crosstalk between these signaling pathways on stiff, collagen-rich environments.  Overall, 
I discovered that β1 integrin and its downstream effector JNK mediate sorafenib 
 99 
 
resistance during tumor stiffening. These results also highlight the need for more 
advanced cell culture platforms, such as this high-throughput PEG-PC system, with 
which to screen chemotherapeutics. 
4.2 Introduction 
 The tumor microenvironment plays an important role in providing a niche to 
nurture the growth of cancer cells [1]. Recently, stromal cells, growth factors, cytokines, 
and ECM proteins in the tumor microenvironment have been implicated in promoting 
resistance to chemotherapeutics as well [2, 3]. Specifically, certain stromal growth factors 
mediate cell proliferation in the presence of otherwise powerful chemotherapeutic drugs. 
For example, hepatocyte growth factor (HGF) imparts resistance to vemurafenib in 
melanoma [4, 5], and TGF-β induces the expansion of cancer stem-like cells, which are 
responsible for chemotherapy-resistance and relapses [6]. These growth factors are 
generally thought to be released by local stromal fibroblasts, which upon DNA-damage 
from treatments with a combination of mitoxantrone and docetaxel, or radiation stimulate 
prostate cancer cell proliferation and invasion through β-catenin signaling [7]. In addition 
to soluble growth factors, a change in adhesive ECM proteins in the tissue can confer 
resistance to chemotherapeutics via integrin-mediated signaling [8-11]. 
 This evolution in the microenvironment during tumor progression is mediated by 
stromal fibroblasts, which differentiate into myofibroblasts [12] and cancer-associated 
fibroblasts (CAFs) [13], and remodel the ECM by breaking down the basement 
membrane and depositing fibril forming collagens [14-16]. The increase in crosslinked 
fibrous collagens results in tissue stiffening [17, 18], which stimulates cell proliferation 
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[17, 19], invasion and intravasation [20, 21], disrupts cell-cell adhesion [22], and alters 
cell sensitivity to growth factors [23], while simultaneously limiting the diffusion of 
therapeutic agents into the tumor [24]. 
I hypothesized that these mechanochemical changes in the ECM during tumor 
progression may induce drug resistance in carcinoma. Testing this hypothesis required a 
drug testing platform that included not only human cell lines and appropriate growth 
factors, but also tailored control over integrin-binding and ECM stiffness. Therefore, I 
applied the high-throughput PEG-PC platform, which was described in chapter 3, as a 
tool for the study to validate this hypothesis.   
The role of stiffness in regulating drug response was explored by Schrader et al., 
who observed a reduction in apoptosis of cells on stiff substrates when treated with 
cisplatin [25]. Also, Zustiak et al. reported cell line-dependent stiffness sensitivity to 
paclitaxel [26].  Sorafenib was developed as a Raf kinase inhibitor [27], and unlike these 
previously tested drugs, there is no obvious link between this signaling pathway and 
ECM stiffness. Phosphorylation of ERK, a downstream effector of Raf kinase, has been 
implicated in controlling cell proliferation during ECM stiffening [19, 28], so I 
hypothesized that sorafenib efficacy could be hampered in stiff environments, 
contributing at least partially to sorafenib's modest clinical efficacy [29]. 
To capture the evolution of the tumor microenvironment during disease 
progression, I formed hydrogel environments with a range of stiffnesses, including either 
basement membrane-like ECM proteins [30], or a collagen-rich inflammatory ECM [21]. 
I examined whether stiff environments protected carcinoma cells from sorafenib 
treatment, and if this drug resistance was mediated by the canonical Rho-ROCK and β1 
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integrin signaling pathways. Motivated by a targeted phospho-proteomic screen, I also 
quantified the role of ERK, Akt, JNK and p38 signaling during cell response to sorafenib 
on stiff substrates. The results demonstrate the utility of the tunable, high-throughput 
PEG-PC biomaterial platform in drug screening, and identify an exciting new mechanism 
to increase the efficacy of sorafenib in stiff tumor environments.  
4.3 Materials And Methods 
4.3.1 Cell culture 
All supplies were purchased from Life Technologies (Carlsbad, CA) unless 
otherwise noted. Human breast cancer cell lines (MDA-MB-231, BT549, and SkBr3) 
were generous gifts from Dr. Shannon Hughes at the Massachusetts Institute of 
Technology, and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) 
at 37ºC and 5% CO2.  Human hepatocellular carcinoma (HCC) cells (HEP3Bs, American 
Type Culture Collection, Manassas, VA) were cultured in modified Eagle's medium 
(MEM) supplemented with 10% FBS and 1% P/S at 37ºC and 5% CO2. MDA-MB-231 
expressing DsRed and DsRed-let7c-sensor were generous gifts from Dr. D. Joseph Jerry 
at the Department of Veterinary and Animal Science, University of Massachusetts 
Amherst. These two cell lines were cultured in DMEM:F12 supplemented with 14 mM 
sodium bicarbonate, 10 mM HEPES, and 10% FBS, 10 μg/mL Insulin, 1x 
antibiotic/antimycotic, 15 μg/mL gentamicin, and 2 mM L-Glutamine. 
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4.3.2 96-well hydrogel platform 
Glass-bottom 96-well plates (no. 1.5 coverslip glass; In Vitro Scientific, 
Sunnyvale, CA) were plasma treated (Harrick Plasma, Ithaca, NY) and subsequently 
methacrylate-silanized with 2 vol% 3-(trimethoxysilyl) propyl methacrylate (Sigma-
Aldrich, St. Louis, MO) in 95% ethanol (adjusted to pH 5.0 with glacial acetic acid) for 5 
min, washed 3 times with 100% ethanol, and dried at 40 °C for 30 min. PEGDMA (Mn 
750, Sigma-Aldrich), from 0.6-9.1 wt%, was combined with 17 wt% 2-
methacryloyloxyethyl phosphorylcholine (PC) (Sigma-Aldrich) in phosphate buffered 
saline (PBS). These PEGDMA crosslinker concentrations tune the Young's moduli of the 
resulting gels from 6 to 400 kPa [31]. Solutions were sterilized with a 0.2 μm syringe 
filter (Thermo Fisher Scientific, Waltham, MA) and degassed by nitrogen sparging for 
30s. Free-radical polymerization was induced by addition of 0.05 wt% ammonium 
persulfate (APS) and 0.125 vol% tetramethylethylenediamine (TEMED, Bio-Rad 
Laboratories, Hercules, CA). Hydrogels of 40 μL per well in the 96-well plates were 
polymerized under nitrogen for 10 min.  
Post-polymerization, hydrogels were allowed to swell for 24 hours in PBS, then 
treated with 100 μL of sulfo-SANPAH (ProteoChem, Denver, CO; 0.6 mg/mL in pH 8.5 
HEPES buffer) under UV light for 20 min, rinsed twice with HEPES buffer, and followed 
immediately by incubation with protein mixtures overnight. ECM protein mixtures were 
defined as either “basement membrane” composed of 46% human collagen IV 
(Neuromics, Edina, MN), 46% human fibronectin (EMD Millipore, Billerica, MA), and 
8% mouse laminin at 5 μg/cm2, buffered in pH 7.0 PBS, or “collagen rich” composed of 
65% rat tail collagen I, 33% human collagen III (FibroGen, San Francisco, CA), and 2% 
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fibronectin at 5 μg/cm2, buffered in pH 3.8 PBS. Post-protein coupling, the gels were 
rinsed twice with PBS, UV-sterilized for 1 h, and rinsed with sterile medium before cell 
seeding.  
4.3.3 Quantification of drug resistance 
Cells were seeded onto gel surfaces at a density of 31,000 cells/cm2 in serum-free 
medium supplemented with 20 ng/mL of platelet-derived growth factor (PDGF-BB, 
eBioscience, San Diego, CA) and 20 ng/mL of epidermal growth factor (EGF, R&D 
Systems, Minneapolis, MN). After 24 h, cells were treated with sorafenib (LC 
Laboratories, Woburn, MA) from 0 to 120 μM, diluted in growth factor-supplemented 
serum-free medium. After 24 h, I measured cell proliferation with CellTiter 96 AQueous 
One Solution Cell Proliferation Assay (Promega, Madison, WI) at 490 nm (BioTek 
ELx800 microplate reader, BioTek, Winooski, VT). The concentration of sorafenib that 
reduced cell proliferation by 50% (IC-50) was calculated with Prism v5.04 (GraphPad 
Software, La Jolla, CA). In some experiments, sorafenib was also co-administered with: 
an anti-β1 integrin antibody (clone P5D2, R&D Systems, 0.5 μg/mL), p160ROCK 
inhibitor (Y-27632, R&D Systems, 10 μM), EGF receptor (EGFR) inhibitor (AG1478, 
AG Scientific, San Diego, CA, 1 μM), JNK inhibitor (SP600125, LC Laboratories, 20 
μM), p38 inhibitor (BIRB796, LC Laboratories, 1 μM), or ERK inhibitor (FR180204, 
Sigma-Aldrich, 20 μM). Dimethyl sulfoxide (Sigma-Aldrich) was used as a vehicle 
control in all experiments. I also verified that cell proliferation measurements 
approximately linearly correlated to cell count (Figure 4.1). 
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Figure 4.1 MTS assay linearly correlates with raw cell counts. 231 cells were seeded 
at different cell densities on 400 kPa gels, and the MTS assay was run 24-hour post-
seeding. The resulting absorbance (proliferation, y-axis) linearly correlates with initial 
cell number (x-axis) with a R2 of 0.9933. Figure adapted with permission from [74]. © 
2014 Elsevier, Inc. 
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4.3.4 Immunofluorescent imaging 
18 mm glass coverslips (Thermo Fisher Scientific, Waltham, MA) were plasma 
treated, methacrylate-silanized, and dried at 120 °C for 15 min. 80 μL PEG-PC hydrogels 
were polymerized with APS and TEMED between a methacrylated-silanized coverslip 
and an untreated coverslip for 20 min on the bench. After polymerization, the hydrogels 
were allowed to swell in PBS, and the non-treated coverslips were removed easily with 
fine forceps.  Swollen gels on coverslips were transferred to 12-well tissue culture dishes, 
coupled with protein mixtures as described above, rinsed 3 times with PBS, and UV-
sterilized for 1 h prior to cell seeding. 
Cells were seeded at a density of 10,000 cells/cm2 in growth factor-supplemented 
serum-free medium and allowed to adhere for 24 hours.  Cells were rinsed three times 
with warm PBS, fixed with 4% formaldehyde, permeabilized with Tris-buffered saline 
(TBS) containing 0.5% Triton X-100 (Promega), and blocked with AbDil (2 wt.% BSA 
in TBS with 0.1% Triton X-100, TBS-T). F-actin was labeled with Alexa Fluor 555-
conjugated phalloidin for 1 h. Vinculin was labeled with a monoclonal mouse anti-
vinculin antibody (Sigma-Aldrich) for 1 h, followed by an anti-mouse FITC secondary 
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h. Cell nuclei 
were labeled with DAPI (MP Biomedicals, Santa Ana, CA) for 5 min. Each sample was 
treated with ProLong Gold antifade reagent for 5 min before imaging on a Zeiss Axio 
Observer Z1 microscope with a 63x oil immersion objective (Carl Zeiss AG, 
Oberkochen, Germany), and images were compiled in ImageJ (NIH, Bethesda, MD). 
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4.3.5 Multiplex phospho-protein quantification 
MDA-MB-231 cells ('231s') were seeded at 50,000 cells/cm2 on 6 and 400 kPa 18 
mm diameter coverslip-mounted gels in 12-well plates. Immediately after seeding, at 0 
min, 30 min, 1 h, 2 h, 4 h, 6 h, and 24 h time points, coverslips were transferred to a new 
12-well plate on ice, the gels were washed once with ice-cold Bioplex cell wash buffer 
(Bio-Rad, Hercules, CA), and lysed with ice-cold lysis buffer (Bioplex cell lysis buffer, 
Bio-Rad) containing protease (EDTA-free Protease Inhibitor Cocktail Tablets, Roche, 
Indianapolis, IN) and phosphatase (2x phosphatase inhibitors cocktail-II, Boston 
Bioproducts, Boston, MA) inhibitors. Separately, cells were allowed to adhere for 24 
hours, treated with sorafenib, and lysates were collected at 0 min, 1 h, 5 h, 15 h, and 24 h 
time points after sorafenib treatment. Total protein concentration was quantified with a 
BCA protein assay (Thermo Scientific, Rockford, IL). Lysate concentrations were 
adjusted to 100 μg/mL, and the phosphorylation levels of ERK1/2, Akt, JNK, and p38 
were quantified with a MAGPIX (Luminex, Austin, TX) with Bio-Plex Pro™ phospho-
ERK1/2, phospho-Akt, phospho-JNK, and phopho-p38 magnetic beads (Bio-Rad), 
according to the manufacturer instructions. 
4.3.6 Quantification of mammary stem/progenitor cells 
 MDA-MB-231s expressing DsRed-let7c-sensor were seeded at 3,100 cells/cm2 on 
18-mm gel-laden coverslips, which were coupled with collagen-rich ECM, in the same 
cell-culture medium. The medium was replenished every other day, and the gels were 
imaged at day 1, 3, 5, and 7. Then the number of red cells was manually counted from the 
images. 
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 When flow cytometry was used to quantify the number of progenitor cells, cells 
were collected from the gels on day 7 and resuspended in 1x PBS supplemented with 0.5 
wt. % of BSA and 1 mM Ethylenediaminetetraacetic acid (EDTA). The cell suspension 
was filtered with a cell strainer (Thermo Fisher Scientific) to eliminate large cell clumps. 
The Fluorescence-Activated Cell Sorting (FACS) data were collected with a total of 
100,000 events using LSRII (BD Biosciences, San Jose, CA) and analyzed with BD 
FACSDiva Software (BD Biosciences).  
4.3.7 Statistical analysis 
A one-way analysis of variance (ANOVA) with a Tukey post-test was performed 
with Prism v5.04 (GraphPad Software). Data are reported as mean ± standard error. p ≤ 
0.05 is denoted with *, ≤ 0.01 with **, and ≤ 0.001 with ***; P > 0.05 is considered not 
significant (“ns”). 
4.4 Results 
4.4.1 Carcinoma cell response to sorafenib on PEG-PC hydrogels 
I created a high-throughput biomaterial platform to rapidly assay cell responses to 
chemotherapeutic drugs in different mechanochemical environments (Figure 4.2). In 
particular, I focused on how these changes perturbed the efficacy of sorafenib, a Raf 
kinase inhibitor approved for thyroid, kidney and liver cancer, but which has had limited 
clinical success [29, 32, 33].  One potential cause of drug resistance by carcinoma cells 
might be the stiffening of the tumor environment itself, and so I quantified the responses 
of a liver cancer cell line and three breast cancer cell lines to sorafenib on PEG-PC of 
increasing stiffness (Figure 4.3).   
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Figure 4.3 Representative images of cells adhering on 165 kPa gels coupled with 
collagen-rich ECM in 96-well plate. (A) MDA-MB-231 (B) BT549 (C)SkBr3 (D) 
HEP3B. Scale bar is 100 μm.  
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In all cell lines, I consistently observed a significant increase in sorafenib IC-50, 
the concentration at which the proliferation was dampened by half, with increasing 
substrate stiffness (Figures 4.4A-B).  I observed this phenomenon on both the basement 
membrane-like ECM (Figure 4.4A), and the collagen-rich ECM (Figure 4.4B), 
demonstrating that this stiffness-induced drug resistance is maintained even with 
alterations in integrin binding. Two of the breast cancer cell lines I tested, the SkBr3s and 
231s, were the most drug resistant cell lines on the basement membrane ECM (Figure 
4.4A). When I normalized the IC-50s within each cell line to the softest condition, I 
observed that these two cell lines also showed the most stiffness-induced resistance to 
sorafenib, with 3.7 and 3 fold increases in IC-50 on the stiffest gels when compared to the 
softest condition, respectively (Figure 4.5A). On the collagen-rich mixture, again the 231 
and SkBr3s were the most drug resistant cell lines (Figure 4.4B), but, interestingly, the 
HEP3B cell line was the most stiffness sensitive (Figure 4.5B). Altogether, on the 
collagen-rich ECM, the SkBr3 and 231 cell lines are more sorafenib resistant across all 
gel conditions. Stiffness increases their sorafenib resistance, but they appear less stiffness 
sensitive than the HEP3Bs because the HEP3Bs are, overall, less resistant to sorafenib. 
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Figure 4.4 Cells on stiff substrates resist sorafenib. The IC-50 (from proliferation 
measurements) of HEP3B (orange), BT-549 (blue), MDA-MB-231 (red), and SkBr3 
(green) cells increases with stiffness on both (A) basement membrane ECM proteins and 
(B) collagen-rich ECM proteins. On the collagen-rich ECM, the same proliferation assay 
without sorafenib at (C) 2 hours and (D) 24 hours post-seeding demonstrates that 
differences in initial cell adhesion or proliferation do not explain the results in A and B 
for each cell line. (E) Resistance to sorafenib of 231 cells is heightened and maintained at 
longer (5 days, red) culture times on the gels. Statistics shown are with respect to the 
softest gel condition, with the exception of the BT549 cells in D which were significantly 
different when comparing 50 and 400 kPa gels. N ≥ 3 independent biological replicates, 
and N = 3 technical replicates. Figure adapted with permission from [74]. © 2014 
Elsevier, Inc. 
E 
A B 
D C 
 112 
 
A 
B 
Basement Membrane ECM
0 100 200 300 400
0
1
2
3
4
5
***
**
*
IC
-5
0 
(N
or
m
al
ize
d)
Young's Modulus (kPa)
Collagen-rich ECM
0 100 200 300 400
0
1
2
3
4
5
HEP3B
BT-549
MDA-MB-231
SkBr3
** **
*
*
Young's Modulus (kPa)
IC
-5
0 
(N
or
m
al
ize
d)
 
Figure 4.5 Normalized cell proliferation in response to stiffness. (A) and (B) are the 
data from Figure 2, re-drawn with each cell line internally normalized to the softest gel 
condition. (A) On the basement membrane proteins, SkBr3 cells were the most stiffness 
sensitive cell line, whereas (B) HEP3B cells were the most stiffness sensitive cell line on 
collagen-rich proteins. Statistics are relative to the soft gel conditions. Figure adapted 
with permission from [74]. © 2014 Elsevier, Inc. 
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Neither initial cell adhesion to the gels, nor proliferation at 24 hours showed the 
same consistent trends as drug resistance, ruling them out as significant contributors to 
sorafenib resistance (Figures 4.4C-D and Figure 4.6). I also cultured the 231 cells for five 
days prior to sorafenib treatment and found that the cells responded to sorafenib in the 
same manner as compared to dosing 24 hours post-seeding, but with larger IC-50s due to 
cell proliferation in the days prior to drug treatment (Figure 4.4E). This result 
demonstrates that the observed stiffness-mediated drug resistance is maintained at longer 
time points of culture. 
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Figure 4.6 Spearman correlation between proliferation and IC-50s. Early cell 
adhesion does not correlate with stiffness-mediated sorafenib resistance. (A) HEP3B, (B) 
MDA-MB-231, (C) BT549, (D) SkBr3. With the exception of the HEP3B cell line (A, 24 
hours only), no cell lines showed a positive Spearman correlation between the MTS 
reading (y-axis) at 2 (circles) or 24-hours (squares) post seeding and the observed IC-50 
value of sorafenib treatment (x-axis). Different colors represent the values at the different 
stiffness gels. Figure adapted with permission from [74]. © 2014 Elsevier, Inc. 
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4.4.2 Cytoskeletal tension and sorafenib resistance  
Given the known role of substrate stiffness in influencing cell proliferation via the 
canonical Rho-ROCK pathway [19, 28], I hypothesized that intracellular tension was the 
most probable mechanism by which increasing stiffness protected cells from sorafenib. I 
quantified cell area and imaged F-actin organization in response to increasing substrate 
stiffness for the two most drug resistant cell lines (231 and SkBr3, Figure 4.7A-D). 
Interestingly, on the collagen-rich ECM, cell spread area had a biphasic dependence on 
substrate stiffness, whereas cell spread area increased with stiffness on the basement 
membrane proteins. This result does not match the observed drug resistance results 
(compare Figures 4.7B and D with Figures 4.4A-B), and implies that intracellular tension 
does not exclusively explain the observed stiffness-mediated resistance on collagen-rich 
ECM.  Figures 4.7A-D also demonstrate that integrin binding (via ECM proteins) 
influences the sensitivity of cell area to substrate stiffness. 
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Figure 4.7 Sorafenib resistance is not mediated by cytoskeletal tension. Both MDA-
MB-231s (A-B) and SkBr3s (C-D) show a biphasic relationship between cell spread area 
and stiffness on the collagen-rich ECM, and increasing spread areas on the basement 
membrane ECM. In A and C, cells were fixed and stained for F-actin (red), vinculin 
(green), and the nucleus (DAPI, blue). (E) MDA-MB-231 stiffness-induced drug 
resistance is significantly reduced when sorafenib is co-administered with an antibody to 
β1 integrin (compare black and blue lines), whereas inhibitors to ROCK (red) and EGFR 
(green) do not affect the stiffness-induced sorafenib resistance. (F) Neither the ROCK 
nor EGFR inhibitors, nor the β1 integrin antibody effectively altered the response to 
sorafenib in the SkBr3s. Statistics are with respect to the softest gel condition. N ≥ 3 
independent biological replicates, and N = 3 technical replicates. Scale bar is 20 µm. 
Figure adapted with permission from [74]. © 2014 Elsevier, Inc. 
 117 
 
I further examined the potential role of intracellular tension in mediating stiffness-
induced sorafenib resistance via ROCK activity. ROCK is a downstream effector of 
RhoA, a GTPase that regulates cell contractility and actin stress fiber formation [34]. I 
co-administered sorafenib with a ROCK inhibitor (Y27632) in both the 231 and SkBr3 
cell lines on the collagen-rich ECM (Figures 4.7E-F). When compared to the sorafenib 
alone condition (black lines), ROCK inhibition (red lines) dampened sorafenib resistance 
across all moduli, except for the stiffest condition; however, even in the presence of 
ROCK inhibitor, the IC-50s still increased with stiffness in both cell lines. Going further, 
I attempted to block cell adhesion to the collagen-rich ECM by co-administering 
sorafenib with a blocking antibody to the β1 integrin subunit (blue lines). Blocking β1 
integrin was significantly effective in the 231 cells at all stiffnesses, but had no effect on 
sorafenib resistance in the SkBr3s, perhaps implying that SkBr3s can survive sorafenib 
treatment in low adhesive environments. Finally, I treated cells with an inhibitor to 
EGFR, given the known role EGFR activation in promoting resistance of several HCC 
cell lines to sorafenib [35], and given the fact that all these experiments are supplemented 
with EGF. EGFR inhibition (green lines) increased the efficacy of sorafenib modestly in 
both cell lines, but the trend of stiffness-induced drug resistance remained. Taken 
together, neither ROCK nor EGFR appears to regulate stiffness-mediated sorafenib 
resistance; however, β1 integrin antibody may be a candidate for co-treatment with 
sorafenib in triple negative breast cancer (the subtype of the 231 cell line), but not HER2 
overexpressing breast cancer (SkBr3 subtype).  
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4.4.3 Signaling pathways activated during ECM stiffening 
Given that β1 integrin antibody was the only effective co-treatment with sorafenib 
in the 231 cells, I investigated a subset of candidate signaling pathways, downstream of 
β1, which might be interfering with sorafenib efficacy. I used a multi-plex MAGPix 
system to quantify the phosphorylation of three members of the MAPK family (ERK1/2, 
JNK, p38), and Akt of the PI3K pathway at multiple time points post-adhesion to the 
softest and stiffest substrates tested in the 231 cell line (Figures 4.8A-D). On both the 
collagen-rich and basement membrane ECMs, I observed an early peak in 
phosphorylation of ERK1/2 and Akt post-adhesion, but there was no difference when 
comparing between the soft and stiff gel conditions. JNK phosphorylation was delayed 
on the basement membrane ECM when compared to the collagen rich ECM, and the 
activity of JNK and p38 was higher on the stiffer gel at all time points on the collagen-
rich ECM. Therefore, changes in JNK signaling could partially explain differences in cell 
behavior on the two protein mixtures, and both JNK and p38 are promising candidates to 
explain sorafenib resistance on stiff substrates. 
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4.4.4 Combinatorial treatment of a JNK inhibitor and sorafenib on stiff substrates 
To determine whether sorafenib treatment perturbed the activity of these signaling 
proteins, I allowed 231 cells to adhere to the two stiffness gels coupled with collagen-rich 
ECM for 24 hours, and performed the MAGPix assay at various time points directly 
following a 15 µM sorafenib treatment. Upon sorafenib treatment, ERK1/2 
phosphorylation on the stiff substrate remained significantly higher than that on the softer 
gel at early time points post-dosing (Figure 4.9A). Akt phosphorylation also peaked in 
the first hour after sorafenib treatment; however, there was no difference in Akt 
phosphorylation between the soft and stiff substrates, which further confirmed that Akt 
signaling was not involved in stiffness-mediated drug resistance (Figure 4.9B). The 
observed peak in Akt might be due to the ability of Ras to mediate signaling through 
PI3K/Akt pathway [36], while sorafenib inhibits the Ras/Raf/MEK/ERK pathway. JNK 
phosphorylation was highest on the stiff substrate, and, unlike ERK and Akt, did not 
change over time (Figure 4.9C). Sorafenib treatment also reduced the stiffness sensitivity 
of p38 phosphorylation (Figure 4.9D).  
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Figure 4.9 Stiffness-induced sorafenib resistance is mediated by JNK activity. 231 
cells on collagen-rich ECM were treated with 15 µM sorafenib, and subsequent 
phosphorylation of ERK1/2, Akt, JNK, and p38 was quantified with a MAGPix assay. 
(A) ERK phosphorylation remained high on stiffer substrate (blue) at early time points 
(x-axis) when treated with sorafenib. (B) Akt phosphorylation peaked at 1 hour post-
sorafenib treatment, but did not vary with stiffness. (C) Sustained phosphorylation of 
JNK was unaffected by sorafenib treatment, and high levels were maintained on the stiff 
substrate. (D) Phosphorylation of p38 in the presence of sorafenib was not significantly 
different between soft and stiff substrates. N ≥ 2 independent biological replicates, and N 
= 3 technical replicates. Statistics are relative to the soft gel condition. Figure adapted 
with permission from [74]. © 2014 Elsevier, Inc. 
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Figure 4.10 Co-administering sorafenib with a JNK inhibitor reduces the stiffness-
induced drug resistance. (A) MTS assays were performed on 231 cells on collagen-rich 
ECM in the presence of sorafenib alone (black), sorafenib plus a pharmacological JNK 
inhibitor (blue, SP600125), sorafenib plus an ERK inhibitor (red, FR18204), or sorafenib 
plus p38 inhibitor (yellow, BIRB796). The sorafenib dose was varied (resulting in an IC-
50, y-axis), while inhibitor concentrations were constant. JNK inhibition reduced both the 
overall sorafenib resistance and stiffness-induced resistance (compare the blue and black 
lines), whereas p38 and ERK inhibitors did not affect sorafenib efficacy. (B) Combining 
either ERK (purple) or p38 (green) inhibitors with JNK inhibitor and sorafenib reversed 
the previously observed effect of inhibiting JNK alone (blue). N ≥ 3 independent 
biological replicates, and N = 3 technical replicates. Statistics are relative to the soft gel 
condition. Figure adapted with permission from [74]. © 2014 Elsevier, Inc.  
A 
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When considering the results in Figures 4.8 and 4.9 together, ERK, p38, and JNK 
were all potential candidates for involvement in stiffness-mediated sorafenib resistance. I 
co-administered sorafenib with inhibitors to each of these molecules (Figure 4.10A), and 
found that JNK inhibition (blue line) both significantly increased sorafenib efficacy, and 
eliminated the impact of substrate stiffness. In hindsight, this result could have been 
anticipated, as JNK was the only signaling molecule both enhanced by substrate stiffness 
during cell adhesion (Figure 4.8C), and unaffected by sorafenib treatment (Figure 4.9C). 
With an expected synergistic effect in mind, I then co-administered sorafenib with JNK 
inhibitor, and either ERK or p38 inhibitors (Figure 4.10B). Strikingly, I found that 
combining either p38 or ERK inhibitors alongside the JNK inhibitor and sorafenib 
treatment reversed the effect of co-administering the JNK inhibitor alone. 
4.4.5 Enrichment of mammary stem/progenitor cells on stiff substrates 
 Cancer stem/progenitor cells (CSC) are notoriously resistant to 
chemotherapeutics, and exposure to chemotherapy can lead to an increase of CSCs 
population [37]. The stemness of cancer cells was also found to be modulated by the 
tumor microenvironment in colon cancer [38]. Therefore, I investigated whether the 
observed drug resistance on stiffer substrates could be caused by an increase in the CSC 
population. Since let-7 microRNAs are present in differentiated cells, but depleted in 
mammary progenitor cells [39], MDA-MB-231s expressing DsRed-let7c-sensor were 
cultured on varying-modulus gels, which were coupled with collagen-rich proteins, for 7 
days. The number of DsRed expressing cells were observed to increase over time, 
indicating an increase in the number of progenitor cells, but there was not any difference 
across stiffnesses (Figure 4.11). The increase in progenitor cells could be due to an 
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increase in the total cell population, as the cells were proliferating. To be more precise, 
flow cytometry was performed to quantitatively measure the fraction of the DsRed 
population (Figures 4.12A-F). The fraction of DsRed cells were similar across all 
stiffnesses, and accounted for approximately 0.2% of the entire population. Thus it can be 
concluded that the stiffness-induced sorafenib resistance was not caused by an increase in 
number of progenitor cells on stiff substrates.    
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Figure 4.11 The number of progenitor cells over time. The total number of mammary 
stem/progenitor cells increases over time, but not regulated by substrate modulus.   
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Figure 4.12 The enrichment of mammary stem/progenitor cells are independent of 
substrate modulus. (A) non-DsRed expressing cells were used as a negative control. (B) 
DsRed expressing cells were used as a positive control. An increase in substrate modulus 
with (C) 23kPa, (D) 165 kPa, and (E) 400 kPa does not significantly change the 
population of stem/progenitor cells (F). Abbreviations: SSC-A: side scatter-area.   
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4.5 Discussion 
Several groups have demonstrated a link between substrate stiffness and cell 
proliferation across a variety of cell types [26, 40-43], and many of these studies have 
linked stiffness sensing, the actin and microtubule cytoskeleton, and the classic Rho-
ROCK pathway. This foundation of work has propelled me and others to determine if this 
pathway, which is known to control cell growth and survival, might also be responsible 
for drug resistance in stiff tumor environments.  For instance, Zustiak et al found that 
paclitaxel, a cytotoxic microtubule stabilizing agent, eliminated stiffness-induced drug 
resistance in most tested cell lines [26].  However, chemotherapies that induce apoptosis 
via non-cytoskeletal pathways, are also affected by substrate stiffness. Schrader et al. 
showed that stiff substrates reduced HCC cell apoptosis when treated with cisplatin, 
which causes apoptosis by crosslinking cellular DNA [25].  These studies motivated me 
to look at how stiffness might perturb the efficacy of a common chemotherapeutic within 
another class of drugs, specifically, sorafenib, a Raf kinase inhibitor that targets the 
Raf/MEK/ERK pathway. I also observed a clear stiffness-induced resistance to sorafenib 
across multiple cell lines. Consistent with Schrader et al., the HCC cell line (HEP3B) was 
the most stiffness-sensitive cell line tested, and showed a positive correlation between 
cell proliferation (at 24 hours) and drug resistance (Figure 4.6A). However, cell 
proliferation did not correlate with drug resistance in any of the other cell lines tested, 
which were all from breast carcinoma; thus the simplest explanation for the results in 
Figure 4.4, that cell proliferation on high stiffnesses was responsible for sorafenib 
resistance, does not hold. The IC-50s for most cell lines are higher on collagen-rich 
proteins than on basement membrane proteins, with the exception of the SkBr3 cell line, 
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which has similar IC-50s on both protein mixtures (Figure 4.4A-B). Yang et al. also 
found that binding of SkBr3 cells to laminin, which is a component in the basement 
membrane mixture, causes substantial resistance to anti-ErbB2 agents [11], possibly 
agreeing with the results in the SkBr3 cells. These results point to maximum possible 
sorafenib resistance in stiff, collagen-rich microenvironments, which represent highly 
progressed tumors. These results implicate tumor stiffening as a cause for the lack of 
success for sorafenib, which boasts a paltry 3-month survival increase in comparison to 
placebo in HCC [29]. 
Integrin binding can mediate cellular responses to substrate stiffness via RhoA 
activity, leading to stress fiber formation, focal adhesion assembly, actomyosin 
contractility, and cell spreading [34, 44, 45]. Although I did observe cell spread area 
changes in response to both stiffness and ECM protein (Figure 4.7A-D), I quantified no 
change in stiffness-induced resistance trend when co-administered sorafenib with ROCK 
inhibitor. Instead, I examined whether integrin-binding mediated this stiffness-induced 
drug response via some other pathway. β1 integrin has a high affinity for collagen [46], 
and increased signaling through β1 integrin binding protects cancer cells (MDA-MB-231 
and MDA-MB-435) against paclitaxel [8] and small cell lung cancer cells against 
doxorubicin, cyclophosphamide, and etoposide [47]. Reducing β1 integrin binding with 
an antibody sensitized the 231 cells to sorafenib, but did not affect the SkBr3s (Figure 
4.7E-F). Park et al. also observed that SkBr3 cells were not responsive to β1 integrin 
inhibition as compared to MDA-MB-231, likely because of their inherently low β1 
integrin expression [9].  
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Ezzoukhry et al. observed that inhibiting EGFR sensitized several HCC cell lines 
to sorafenib treatment [35]; however, I found that co-treatment of a pharmacological 
EGFR inhibitor with sorafenib in both MDA-MB-231 and SkBr3 cells only affected 
sorafenib efficacy on soft gels (Figure 4.7E-F). Given that integrin binding to the ECM 
can enhance EGFR phosphorylation in the absence of ligand binding [48], it is possible 
that, at lower stiffnesses, β1 integrin predominantly mediates signaling through EGFR 
phosphorylation in the absence of ligand binding [49], but not at higher stiffness.   
 I found that JNK was the key mediator of sorafenib resistance on stiff substrates 
(Figures 4.8-4.10). Activation of JNK has been reported to mediate either pro-apoptotic 
or anti-apoptotic signaling pathways depending on stimuli [50, 51], with parallel 
contradictory roles in vivo, either supporting tumor growth [52-55] or suppressing 
tumorigenesis [56-59]. My results indicate a role for JNK in enhancing cell survival 
during sorafenib treatment, and for the first time I show that JNK activation is regulated 
by substrate stiffness. The high activity of JNK on stiff substrates implicates high Rac1 
activity and low RhoA activity [49, 60], and low RhoA activity is consistent with the 
overall lack of stress fiber formation observed in 231 cells [61], regardless of stiffness 
(Figure 4.7A). Further, ROCK inhibition did not affect the stiffness-induced drug 
resistance. Finally, RhoA/ROCK can activate ERK [28], and indirectly activates PI3K-
Akt pathway [62], supporting my observations of a lack of stiffness-dependent ERK or 
Akt phosphorylation (Figures 4.8A-B). 
 Conversely, when we quantified phospho-protein activity in the presence of 
sorafenib and PDGF and EGF, we observed that ERK phosphorylation was higher on the 
stiff substrate.  This is consistent with other observations that cells on stiff substrates are 
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more sensitive to EGF stimulation in comparison to those on soft substrates (Figures 
4.9A-B) [19, 23]. However, this transient ERK activation on stiff substrates did not 
prolong cell survival in the presence of sorafenib treatment (Figure 4.10A). Combining 
both p38 and JNK inhibitors alongside sorafenib reversed the effect of inhibiting JNK 
alone, suggesting negative crosstalk between JNK and p38. Other studies have reported 
this antagonism between p38 and JNK before [63, 64]. I observed this same rescue of 
stiffness-mediated sorafenib resistance when I co-administered JNK and ERK inhibitors, 
which is also supported by reports of JNK and ERK antagonism [65, 66]. 
Overall, these results elucidate a role for JNK in mediating resistance to sorafenib 
through β1 integrin binding to collagen-rich environments (Figure 4.13). β1 integrin 
activation leads to Src-mediated phosphorylation of EGFR [49, 67], which activates 
Ras/Raf/MEK/ERK and PI3K/Vav2/Rac1/JNK. Inhibiting EGFR improved the efficacy 
of sorafenib on soft gels (Figure 4.7E), which I attribute to low β1 integrin affinity [49]. 
At high stiffness, however, EGFR inhibition had no effect, as integrin clustering 
increases, recruiting the FAK-Cas complex and activating Ras/Rac1/JNK [68-70]. 
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Figure 4.13 Proposed role for JNK in stiffness-mediated sorafenib resistance. I 
propose that stiff gels increase β1 clustering when bound to ECM, increasing the 
activation of the Ras-Raf-MEK pathways, which is targeted by sorafenib, but also Rac1 
and downstream JNK activation, offering increased cell proliferation and anti-apoptosis 
signaling, protecting cells from sorafenib. Inhibiting ERK and p38 are known to block 
JNK inhibition, providing a reversal of the observed ability of JNK inhibition to improve 
sorafenib efficacy on stiff substrates. Blue boxes indicate the microenvironment changes 
that are controlled, green boxes indicate the biological responses that are measured, and 
red letters indicates inhibitors used to perturb the signaling pathways. Figure adapted 
with permission from [74]. © 2014 Elsevier, Inc. 
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In sum, the ability to capture the cell-matrix interactions present in the in vivo 
tumor microenvironment could profoundly influence our ability to understand true drug 
efficacy in vitro. Others have created similar high-throughput biomaterial platforms 
including ECM microarrays [71], contact-printed microarrays [72], PEG microwells [73], 
and 2D biomaterials in 96-well plates [26, 41]. The most promising of these approaches 
have each used polyacryamide (PAA) gels, but require either a complicated plate insert 
[41], or manually placing gels into individual wells [26]. My method of casting PEG-PC 
gels allowed me to quickly make multiple uniform gels of varying stiffnesses in multiple 
96-well plates at the same time, and does not require fabrication of any special devices 
(Figure 4.2). My high-throughput PEG-PC platform allowed me to identify β1 integrin, 
and its downstream effector, JNK, as mediators of tissue stiffening-induced drug 
resistance. Co-administering sorafenib with inhibitors to either of these targets equally 
eliminated stiffness-induced resistance in the 231 cells (Figure 4.14). However, when co-
administering sorafenib with inhibitor to JNK, p38, and ERK in SkbR3 cells, the IC-50s 
were dampend, but the stiffness-induced drug resistance trend remained (Figure 4.15). 
This results were further supported with the measurement of phosphorylation levels of 
these molecules on soft and stiff substrates (Figure 4.16).     
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Figure 4.14 Inhibition of JNK shows similar results to treating with a β1 integrin 
antibody. Inhibition of β1 integrin or its downstream effector JNK reduces the overall 
IC-50 and eliminates the stiffness-mediated drug resistance trend. Statistics shown are 
with respect to the softest gel condition. Figure adapted with permission from [74]. © 
2014 Elsevier, Inc. 
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Figure 4.15 Inhibitions of JNK, ERK, and p38 do not dampen the stiffness induced 
drug resistance in SkBr3 cells.  Inhibition of these molecule enhance the effectiveness 
of sorafenib at all conditions, but does not eliminate the stiffness-induced sorafenib 
resistance. 
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Figure 4.16 SkBr3s' Akt phosphorylation is increased on stiff subtrate. (B) Akt is the 
only signaling molecule that shows a modest increase in phosphorylation on stiff gels 
whereas the phosphorylation of (A) ERK, (C) JNK, (D) p38 are similar between soft and 
stiff substrates. 
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4.6 Conclusions 
I propose that systems like my high-throughput PEG-PC hydrogel platform are 
critical for future screening of potential chemotherapeutics, as well as for discovery of 
possible mechanisms for failed efficacy of previously promising targets. With my 
platform, I discovered that the efficacy of sorafenib in carcinoma could potentially be 
increased by co-administering inhibitors to β1 integrin or JNK, which could not have 
been appreciated on traditional tissue culture plastic plates. My results highlight the 
importance of incorporating relevant tissue stiffness and integrin binding ligands into the 
high-throughput drug screening process to increase the success of drugs in the 
development pipeline.
 137 
 
4.7 References 
[1] Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer 
progression. J Cell Biol 2012;196:395-406. 
[2] Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp 
Cell Res 2010;316:1324-31. 
[3] Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med 
2012;18:1332-4. 
[4] Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread 
potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 
2012;487:505-9. 
[5] Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour 
micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. 
Nature 2012;487:500-4. 
[6] Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, et al. TGF-β 
inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin 
Invest 2013;123:1348-58. 
[7] Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, et al. Treatment-induced 
damage to the tumor microenvironment promotes prostate cancer therapy resistance 
through WNT16B. Nat Med 2012;18:1359-68. 
 138 
 
[8] Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast 
cancer cells. Oncogene 2001;20:4995-5004. 
[9] Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, et al. Beta1 integrin 
inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and 
distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. 
Cancer Res 2006;66:1526-35. 
[10] Liu S, Wang J, Niu W, Liu E, Wang J, Peng C, et al. The beta6-integrin-ERK/MAP 
kinase pathway contributes to chemo resistance in colon cancer. Cancer Lett 
2013;328:325-34. 
[11] Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, et al. Disruption of laminin-
integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 
antagonists. Cancer Res 2010;70:2256-63. 
[12] Rdnnov-jessen L, Petersen OW, Koteliansky V, Bissell MJ. The origin of the 
myofibroblasts in breast cancer. J Clin Invest 1995;95:859-73. 
[13] Paraiso KH, Smalley KS. Fibroblast-mediated drug resistance in cancer. Biochem 
Pharmacol 2013;85:1033-41. 
[14] Vong S, Kalluri R. The role of stromal myofibroblast and extracellular matrix in 
tumor angiogenesis. Genes Cancer 2011;2:1139-45. 
[15] Otranto M, Sarrazy V, Bonte F, Hinz B, Gabbiani G, Desmouliere A. The role of the 
myofibroblast in tumor stroma remodeling. Cell Adh Migr 2012;6:203-19. 
 139 
 
[16] Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular 
carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011;21:35-43. 
[17] Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix 
crosslinking forces tumor progression by enhancing integrin signaling. Cell 
2009;139:891-906. 
[18] Samani A, Zubovits J, Plewes D. Elastic moduli of normal and pathological human 
breast tissues: an inversion-technique-based investigation of 169 samples. Phys Med Biol 
2007;52:1565-76. 
[19] Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. 
Tensional homeostasis and the malignant phenotype. Cancer Cell 2005;8:241-54. 
[20] Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, 
invasion, and metastasis. Cell 2006;124:263-6. 
[21] Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen 
scaffold and tumor evolution. Curr Opin Cell Biol 2010;22:697-706. 
[22] Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of 
a tumor cell. Cancer Metastasis Rev 2009;28:113-27. 
[23] Kim J, Asthagiri AR. Matrix stiffening sensitizes epithelial cells to EGF and enables 
the loss of contact inhibition of proliferation. J Cell Sci 2011;124:1280-7. 
[24] Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular 
matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503. 
 140 
 
[25] Schrader J, Gordon-Walker TT, Aucott RL, van Deemter M, Quaas A, Walsh S, et 
al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in 
hepatocellular carcinoma cells. Hepatology 2011;53:1192-205. 
[26] Zustiak S, Nossal R, Sackett DL. Multiwell stiffness assay for the study of cell 
responsiveness to cytotoxic drugss. Biotechnol Bioeng 2013;9999:1-8. 
[27] Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the 
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis 
in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8. 
[28] Khatiwala CB, Kim PD, Peyton SR, Putnam AJ. ECM compliance regulates 
osteogenesis by influencing MAPK signaling downstream of RhoA and ROCK. J Bone 
Miner Res 2009;24:886-98. 
[29] Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: 
a systematic review. Dig Dis Sci 2012;57:1122-9. 
[30] Tian B, Li Y, Ji XN, Chen J, Xue Q, Ye SL, et al. Basement membrane proteins play 
an active role in the invasive process of human hepatocellular carcinoma cells with high 
metastasis potential. J Cancer Res Clin Oncol 2005;131:80-6. 
[31] Herrick WG, Nguyen TV, Sleiman M, McRae S, Emrick TS, Peyton SR. PEG-
phosphorylcholine hydrogels as tunable and versatile platforms for mechanobiology. 
Biomacromolecules 2013;14:2294-304. 
 141 
 
[32] Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib 
for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III 
treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-
8. 
[33] Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone 
K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 
2008;26:4714-9. 
[34] Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001;114:2713-22. 
[35] Ezzoukhry Z, Louandre C, Trecherel E, Godin C, Chauffert B, Dupont S, et al. 
EGFR activation is a potential determinant of primary resistance of hepatocellular 
carcinoma cells to sorafenib. Int J Cancer 2012;131:2961-9. 
[36] Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk 
and compensation. Trends Biochem Sci 2011;36:320-8. 
[37] Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis 
of evil in the war on cancer. Oncogene 2010;29:4741-51. 
[38] Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, 
Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the 
microenvironment. Nat Cell Biol 2010;12:468-76. 
 142 
 
[39] Tao L, Roberts AL, Dunphy KA, Bigelow C, Yan H, Jerry DJ. Repression of 
mammary stem/progenitor cells by p53 is mediated by Notch and separable from 
apoptotic activity. Stem Cells 2011;29:119-27. 
[40] Klein EA, Yin L, Kothapalli D, Castagnino P, Byfield FJ, Xu T, et al. Cell-cycle 
control by physiological matrix elasticity and in vivo tissue stiffening. Curr Biol 
2009;19:1511-8. 
[41] Mih JD, Sharif AS, Liu F, Marinkovic A, Symer MM, Tschumperlin DJ. A 
multiwell platform for studying stiffness-dependent cell biology. PLoS One 
2011;6:e19929. 
[42] Tilghman RW, Cowan CR, Mih JD, Koryakina Y, Gioeli D, Slack-Davis JK, et al. 
Matrix rigidity regulates cancer cell growth and cellular phenotype. PLoS One 
2010;5:e12905. 
[43] Ulrich TA, de Juan Pardo EM, Kumar S. The mechanical rigidity of the extracellular 
matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res 
2009;69:4167-74. 
[44] Geiger B, Spatz JP, Bershadsky AD. Environmental sensing through focal 
adhesions. Nat Rev Mol Cell Biol 2009;10:21-33. 
[45] Wang HB, Dembo M, Hanks SK, Wang Y. Focal adhesion kinase is involved in 
mechanosensing during fibroblast migration. Proc Natl Acad Sci U S A 2001;98:11295-
300. 
 143 
 
[46] Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci 
2006;119:3901-3. 
[47] Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. 
Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a 
mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 
1999;5:662-8. 
[48] Cabodi S, Moro L, Bergatto E, Boeri Erba E, Di Stefano P, Turco E, et al. Integrin 
regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. 
Biochem Society Transactions 2004;32:438-42. 
[49] Huveneers S, Danen EHJ. Adhesion signaling - crosstalk between integrins, Src and 
Rho. J Cell Sci 2009;122:1059-69. 
[50] Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? 
Nat Rev Drug Discov 2003;2:554-65. 
[51] Tournier C. The 2 faces of JNK signaling in cancer. Genes Cancer 2013;4:397-400. 
[52] Cellurale C, Sabio G, Kennedy NJ, Das M, Barlow M, Sandy P, et al. Requirement 
of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol 
2011;31:1565-76. 
[53] Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. Survival signaling mediated by 
c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 2002;32:201-5. 
 144 
 
[54] Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-kappa B activity 
enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 
activation. Proc Natl Acad Sci U S A 2006;103:10544-51. 
[55] Wang J, Kuiatse I, Lee AV, Pan J, Giuliano A, Cui X. Sustained c-Jun-NH2-kinase 
activity promotes epithelial-mesenchymal transition, invasion, and survival of breast 
cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer 
Res 2010;8:266-77. 
[56] Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, et al. Role of 
JNK in mammary gland development and breast cancer. Cancer Res 2012;72:472-81. 
[57] Cellurale C, Weston CR, Reilly J, Garlick DS, Jerry DJ, Sluss HK, et al. Role of 
JNK in a Trp53-dependent mouse model of breast cancer. PLoS One 2010;5:e12469. 
[58] Das M, Garlick DS, Greiner DL, Davis RJ. The role of JNK in the development of 
hepatocellular carcinoma. Genes Dev 2011;25:634-45. 
[59] Hübner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-kyros J. JNK and 
PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. 
Proc Natl Acad Sci U S A 2012;109:12046-51. 
[60] Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, et al. The small GTP-
binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling 
pathway. Cell 1995;81:1137-46. 
[61] Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279:509-14. 
 145 
 
[62] Yu H, Mouw JK, Weaver VM. Forcing form and function: biomechanical regulation 
of tumor evolution. Trends Cell Biol 2011;21:47-56. 
[63] Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. p38alpha 
suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. 
Nat Genet 2007;39:741-9. 
[64] Wada T, Stepniak E, Hui L, Leibbrandt A, Katada T, Nishina H, et al. Antagonistic 
control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ 2008;15:89-93. 
[65] Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK 
signaling pathways in the regulation of cell survival. FASEB J 2008;22:954-65. 
[66] Shen YH, Godlewski J, Zhu J, Sathyanarayana P, Leaner V, Birrer MJ, et al. Cross-
talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks 
ERK activation by mitogenic factors. J Biol Chem 2003;278:26715-21. 
[67] Meng F, Lowell CA. A beta 1 integrin signaling pathway involving Src-family 
kinases, Cbl and PI-3 kinase is required for macrophage spreading and migration. The 
EMBO Journal 1998;17:4391-403. 
[68] Hirsch E, Barberis L, Brancaccio M, Azzolino O, Xu D, Kyriakis JM, et al. 
Defective Rac-mediated proliferation and survival after targeted mutation of the beta1 
integrin cytodomain. J Cell Biol 2002;157:481-92. 
 146 
 
[69] Almeida EA, Ilić D, Han Q, Hauck CR, Jin F, Kawakatsu H, et al. Matrix survival 
signaling from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J 
Cell Biol 2000;149:741-54. 
[70] Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, et al. Differential 
regulation of cell motility and invasion by FAK. J Cell Biol 2003;160:753-67. 
[71] Flaim CJ, Chien S, Bhatia SN. An extracellular matrix microarray for probing 
cellular differentiation. Nat Methods 2005;2:119-25. 
[72] Anderson DG, Putnam D, Lavik EB, Mahmood TA, Langer R. Biomaterial 
microarrays: rapid, microscale screening of polymer-cell interaction. Biomaterials 
2005;26:4892-7. 
[73] Khademhosseini A, Langer R, Borenstein J, Vacanti JP. Microscale technologies for 
tissue engineering and biology. Proc Natl Acad Sci U S A 2006;103:2480-7. 
[74] Nguyen TV, Sleiman M, Moriarty T, Herrick WG, Peyton SR. Sorafenib resistance 
and JNK signaling in carcinoma during extracellular matrix stiffening. Biomaterials 
2014;35:5749-5759. 
 
  
 147 
 
CHAPTER 5 
 
A COMPARISON BETWEEN 2D AND 3D PLATFORMS FOR CANCER 
DRUG SCREENING 
 
5.1 Abstract 
 The tumor microenvironment plays an important role in providing a niche to 
nurture tumor growth and promote drug resistance. Various platforms have been 
developed to recapitulate many key features of the tumor ECM. I have taken a holistic 
approach to compare the drug response of the MDA-MB-231, an EGFR overexpressing 
cell line, and SkBr3, a HER2 overexpressing cell line, across different types of two and 
three dimensional (2D and 3D) platforms. I have tested sorafenib (a Raf inhibitor), 
lapatinib (an EGFR/HER2 inhibitor), temsirolimus (a mTOR inhibitor), and doxorubicin 
(a cytotoxic drug), and observed that the sensitivity of cell-drug interaction to 
microenvironment is dependent on both drug type and cell type. The IC-50s of SkBr3s 
when treated with sorafenib and temsirolimus were most sensitive to the change in 
platform, whereas those of 231s were sensitive to the platform type when treated with 
sorafenib and lapatinib. The IC-50 of both cell lines, when treated with doxorubicin, were 
not sensitive to the type of platform. Both HER3 and EGFR phosphorylation in SkBr3s 
were found to be sensitive to the change in the surrounding microenvironment whereas 
HER2 phosphorylation was not. Long-term culture of SkBr3 cells with lapatinib induced 
an upregulation of Insulin Receptor (IR) and its downstream effector ERK in 2D, but not 
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in 3D. These results provide insights into how the interaction between cell and 
microenvironment influences their response to drug and may guide future development of 
biomaterial platforms for drug screening.      
5.2 Introduction 
 Many groups have developed various cell culture platforms in both 2D and 3D 
that are capable of capturing the key features of the tumor microenvironment to study 
cellular response to chemotherapeutics. For example, I have previously developed a high-
through put drug screening tool based on PEG-PC hydrogel system, whereas others have 
done so with PAA hydrogels [1,2], and all of these systems can be easily integrated with 
the traditional high-throughput screening of drug compounds in 96- or 384-well plates. 
Other high-throughput systems, which are more complicated to fabricate, have also been 
developed such as PEG microwells [3] and microarray for cell-based drug screening [4]. 
In addition, cell-drug interaction can be studied in 3D biomaterial scaffolds such as PEG-
based hydrogels that encapsulated single cell [5] or spheroids [6,7], or gelatin hydrogel 
encapsulating spheroids [8]. Other 3D spheroid models include various methods that 
induce spheroid formation through allowing aggregation of non-adherent cells such as 
agarose [9] or PDMS [10] coated plates.  
 Each type of these models has advantages and drawbacks with respect to 
recapitulation of the complex biology, ease of fabrication and use, cost, etc. As compared 
with 3D models, the 2D platforms are easier to fabricate and scale up for high-throughput  
screening; however, these models can only capture the tissue mechanical properties and 
allow highly-controlled bioconjugation of integrin binding sites. They cannot recapitulate 
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the 3D microenvironment that cells experience in vivo. Some 3D models can capture the 
three dimensional geometry, modulus, integrin binding sites, and MMP degradable sites 
that allow cells to remodel the environment. For instance, Leight et al. developed a 3D 
PEG-based platform with MMP-degradable and MMP sensor peptides to study the 
relationship between RAF inhibitors and MMP activity of metastatic melanoma cells [5]. 
However, single cells encapsulated in these 3D materials lack the in vivo cell-cell contact. 
Cadherins, which mediate cell-cell contact, can crosstalk with other growth factors 
receptors such as EGFR [11], HGFR, and FGFR [12] followed by activation of 
downstream signaling pathways such as Wnt signaling [12] or MAPK [13] that can 
promote survival in the presence of chemotherapeutics [14]. Thus, the spheroid models 
allow cells to establish complex cell-cell and cell matrix interactions and capture certain 
features of human in vivo tissues such as histomorphology, function, and 
microenvironments [15]; therefore, they are usually touted as an ideal model for 
preanimal and preclinical drug screening to identify promising drug candidates [9]. 
However, it takes time for spheroid culture, and it is also hard to scale-up for high-
throughput screening. 
 To identify an appropriate model for drug screening, I investigated cell-drug 
interaction across multiple platforms: the common tissue culture plastic plate, 2D 
hydrogel platform, 3D platform that encapsulates single cell or spheroid. Since variation 
in modulus is known to affect cellular response to drugs [1,16,17], I considered two 
different moduli for each platform. I applied the previously developed 2D PEG-PC 
platform [16,18] and the 3D PEG-Maleimide (PEG-MAL) system, which is well-
characterized by Phelps et al. [19]. PEG-MAL can be crosslinked by thiol containing 
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crosslinker following Micheal-type addition, which requires a nucleophilic buffering 
reagent such as TEOA or HEPES instead of using toxic free-radicals and UV light [19]. I 
tested 3 targeted drugs, which target the two most common cell proliferation pathways 
(temsirolimus - Akt/mTOR and sorafenib - Raf/MEK/ERK) and two of the most well-
characterized receptor tyrosine kinases (lapatinib - EGFR and HER2), and one cytotoxic 
drug (doxorubicin). I also examined the sensitivity of RTK receptors to modulus in 3D 
under growth factor stimulation and the influence of 2D and 3D platforms to RTKs' 
phosphorylation and downstream signaling in drug-treated cells.   
5.3 Materials And Methods 
5.3.1 Cell culture 
 All supplies were purchased from Life Technologies (Carlsbad, CA) unless 
otherwise noted. Human breast cancer cell lines (MDA-MB-231 and SkBr3) were 
generous gifts from Dr. Shannon Hughes at the Massachusetts Institute of Technology, 
and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) at 37ºC and 5% 
CO2. 
5.3.2 Spheroids culture 
 The lyophilized poly(N-isopropylacryamide)-poly(ethylene glycol) (PNIPAAm-
PEG, Cosmo Bio, Carlsbad, CA) was reconstituted in cell culture medium for a day and 
kept in the refrigerator for long-term storage. All cell suspensions were prepared at a 
density between 1-1.5 million cells per mL. An appropriate volume of cell suspension 
was added into PNIPAAm-PEG solutions to make 100,000 cells/mL for SkBr3s and 
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167,000 cells/mL for 231s. The gel solution was kept on ice to prevent early gelation. 
Gels with 150 μL volume  were pipetted into a 6-well plate, and the plates were incubated 
in the incubator for 10-15 minutes to induce gelation. After gelation, cell culture medium 
was added to the wells. Cells were cultured to grow into spheroids for 14 days, and the 
medium was replenished every other day. 
5.3.3 Hydrogel mechanical characterization 
 Hydrogels polymerized from 4-arm PEG-maleimide (20 kDa, PEG-MAL, Jenkem 
Technology USA, Plano, TX) were used as a platform to study the response of cells to 
drugs in 3D. PEG-MAL solutions were prepared at 10 wt % and 20 wt %, and PEG 
dithiol (average Mn 1000, Sigma-Aldrich, St. Louis, MO) was dissolved in 
triethanolamine (TEA, pH ~ 7.4) at concentrations of 100 and 200 mg/mL. 
Polymerization of PEG-MAL gels were induced by combining 10 and 20 wt % PEG-
MAL with 100 and 200 mg/mL of PEG dithiol, respectively (9:1 PEG-MAL:PEG dithiol 
by volume). Hydrogel cylinders for mechanical compression testing were formed in 5-
mm Teflon molds and swelled in PBS for 24 h. Post swelling, hydrogel dimensions were 
measured with a digital caliper, and mechanical compression tests were performed with a 
TA Instruments (New Castle, DE) AR-2000 rheometer at a 2 μm/s strain rate. The 
Young’s modulus (E) for each hydrogel was calculated by plotting the measured normal 
force between 0 and 4% strain and dividing the slope of the best-fit linear regression by 
the hydrogel cross-sectional area. 
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5.3.4 Quantification of drug response 
5.3.4.1 Spheroids in 3D PEG-MAL hydrogels 
 The medium in the 6-well plate that had spheroids cultured in PNIPAAm-PEG 
was removed. 4 mL of cold serum-free DMEM supplemented with 1% pen/strep were 
added to each of the well, and the plate was kept on ice for 5 minutes to ensure the 
complete dissolution of PNIPAAm gels. The spheroids in suspension were transferred 
into 2 15-mL tubes with equal volume in each, and cut pipette tips were used to handle 
the spheroids in order to reduce the shear stress. The tubes were kept on ice for 30 
minutes to allow the spheroids to settle at the bottom. After 30 minutes, the medium was 
carefully removed so that the spheroids were not disturbed. Then the spheroids in each 
tube were resuspended in 10 wt % and 20 wt % PEG-MAL dissolved in serum-free 
DMEM. Cell binding peptide CRGD (Genscript, Piscataway, NJ) was added to the PEG-
MAL solutions to make 2 mM final concentration. The gels were made in a 48-well plate 
by combining 9 μL of PEG-MAL with 1 µL of PEG dithiol in TEOA. The gel was 
allowed to polymerize for 5 minutes before addition of either serum-free DMEM 
supplemented with 1% P/S, 20 ng/mL of epidermal growth factor (EGF, R&D Systems, 
Minneapolis, MN) and 20 ng/mL of platelet-derived growth factor (PDGF-BB, 
eBioscience, San Diego, CA) or DMEM with 1% P/S and 10% FBS. To ensure the 
consistency among experiments, the amount of spheroids collected from 1 PNIPAAm 
gels were consistently transfered to 9 PEG-MAL gels. After 24 h, spheroids were treated 
with lapatinib (0-80 μM, LC Laboratories, Woburn, MA), sorafenib (0-64 μM, LC 
Laboratories), temsirolimus (0-80 μM, Selleckchem, Houston, TX), or doxorubicin (0-20 
μM, LC Laboratories). All drugs were dissolved in the same type of medium as the 
 153 
 
spheroids prior to drug treatment. Dimethyl sulfoxide (DMSO, Sigma-Aldrich) was used 
as a vehicle control in all experiments. After 48 h of drug treatment, cell viability was 
quantified by CellTiter Glo® Luminescent Cell Viability Assay (Promega, Madison, 
WI), which measured the amount of ATP in the cells. After 40 minutes of incubation, the 
plate were read with the Synergy 2 Multi-Mode Reader (BioTek, Winooski, VT). The IC-
50s were calculated by using the Excel's non-linear curve fitting  of the data.   
5.3.4.2 Single cells in 3D PEG-MAL hydrogels 
 Cells cultured on tissue culture flask were collected and resuspended in PEG-
MAL solutions at the concentration of 555,556 cells/mL (5,000 cells per gel). PEG-MAL 
gels including 2 mM RGD were made as described above and kept in serum-free DMEM 
with growth factors. After 24 h, the cells were treated with similar drugs described above. 
5.3.4.3 Cells on 2D PEG-PC hydrogels 
 2D PEG-PC hydrogels in the 96-well plate and protein coupling were prepared as 
described previously [16]. PC was used at 17 wt % (0.6M), and PEG was used at 1.1 wt 
% (0.015 M) and 3.2 wt % (0.043 M) to make 10 and 33 kPa gels, respectively. Collagen 
I was coupled to the gel surface at 3.3 μg/cm2. Cells were seeded at 10,000 cells per well 
in serum-free DMEM with growth factors. After 24 h, the cells were treated with similar 
drugs described above.  
5.3.4.4 Cells on tissue culture plastic plate 
 Cells were seeded at 5,000 cells per well in serum containing medium. After 24 h, 
the medium was replaced with serum-free medium supplemented with EGF and PDGF 
growth factors. After 24 h, cells were treated with similar drugs. 
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 5.3.5 Quantification of cell number in spheroids in PEG-MAL gels 
 In order to quantify the total number of cells in each of the PEG-MAL gel 
encapsulating spheroids, the total amount of DNA in spheroids was quantified with 
CyQUANT Cell Proliferation Assay Kit (Life Technologies). The assay was prepared by 
mixing the 1X cell lysis buffer with the Cyquant GR Dye (1:400, Dye:Lysis buffer). The 
gels were removed from the plate with a spatula and placed in 1.5 mL microcentrifuge 
tubes. All tubes were flash-frozen with liquid nitrogen. 200 μL of the assay were added to 
the tube. The hand-held biovortexer (Research Products International, Mt Prospect, IL) 
was used to mechanically break down the gels and enhanced the release of the dye into 
the solution. The solutions were transfer to a 96-well plate, and the fluorescent intensity 
was read at 480/520 excitation/emission with the Synergy 2 plate reader. 
5.3.6 EGF stimulation of spheroids in PEG-MAL gels 
 Spheroids were encapsulated in 10 and 20 wt %  PEG-MAL with RGD binding 
peptides and serum-starved for 24 h. Then spheroids were stimulated with 100 ng/mL of 
EGF, and cell lysates were collect at 10, 30, and 60 min. After 1 h, EGF medium was 
replaced with serum-free medium, and cell lysates were collected at 7 and 24 h time 
points. Cell lysis buffer (MILLIPLEX® MAP Phospho Mitogenesis RTK Magnetic 
Bead, EMD Millipore, Billerica, MA) was supplemented with protease (EDTA-free 
Protease Inhibitor Cocktail Tablets, 1 tablet in 3 mL, Roche, Indianapolis, IN) and 
phosphatase (2x phosphatase inhibitors cocktail-II, Boston Bioproducts, Boston, MA) 
inhibitors, 1 mM of phenylmethylsulfonyl fluoride (PMSF, Thermo Scientific, Rockford, 
IL), 5 μg/mL of pepstatin (Thermo Fisher Scientific, Waltham, MA), 10 μg/mL of 
leupeptin (Thermo Fisher Scientific), 1 mM of sodium pyrophosphate (Thermo Fisher 
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Scientific), 25 mM of β-glycerophosphate (Santa Cruz, Dallas, TX), 1 mM of sodium 
orthovanadate (MP Biomedicals, Solon, OH). At each time point, the gels were washed 
with ice-cold 1X PBS, transfered to the tubes, frozen with liquid nitrogen, and stored at -
80ºC. Multiple gels were combined in order to collect enough proteins for each of the 
condition. When collecting lysates, samples were allowed to thaw on ice for 20 minutes 
before addition of cell lysis buffer. A biovortexer was used to enhance the release of the 
proteins to the solution. Total protein concentration was quantified with a BCA protein 
assay (Thermo Scientific). Lysate concentrations were adjusted to 120 μg/mL, and the 
phosphorylation levels of c-MET/HGFR, EGFR, ErbB2/HER2, ErbB3/HER3, 
ErbB4/HER4, IGF-1R, IR were quantified with a MAGPIX (Luminex, Austin, TX) with 
the MILLIPLEX® MAP Phospho Mitogenesis RTK Magnetic Bead (EMD Millipore) 
according to the manufacturer instructions.   
5.3.7 Long-term lapatinib treatment on 2D and in 3D 
 SkBr3 single cells were either encapsulated in PNIPAAm-PEG gels or seeded on 
a plastic 6-well plate. Post encapsulation/seeding, cells were kept in cell culture medium 
with either 1.25 μM of Lapatinib or  DMSO control. After 14 days, both cells on plastic 
plate and in gels were serum-starved for 24 h. Then cells were stimulated with 10% 
serum medium for 15 min, and cell lysates were collected. The phosphorylation levels of 
similar RTKs and downstream signaling molecules (ERK1/2, Akt, JNK, Bio-Plex Pro™ 
phospho-ERK1/2, phospho-Akt, phospho-JNK, Bio-Rad Laboratories, Hercules, CA) 
were quantified.  
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5.3.8 Statistical Analysis 
 Prism v5.04 (GraphPad Software) was used to perform unpaired Student's t-test, a 
one-way analysis of variance (ANOVA) with a Tukey post-test, and a two-way ANOVA. 
Data are reported as mean ± standard error. p ≤ 0.05 is denoted with *, ≤ 0.01 with **, 
and ≤ 0.001 with ***; P > 0.05 is considered not significant (“ns”). 
5.4 Results 
5.4.1 The influence of platform to the IC-50 is drug-type dependent  
 I have evaluated drug response across 4 different classes of drugs with two cell 
lines on classic plastic surfaces, 2D gel surfaces, and within 3D gels (either as single cells 
or spheroids in serum or serum-free medium) to identify the appropriate model for each 
type of drug mechanism (Figure 5.1A). The drugs include sorafenib, which targets Raf 
kinase in the Raf/MEK/ERK pathway, lapatinib, which targets EGFR/HER2 receptor 
tyrosine kinases (RTK), temsirolimus, which targets mTOR in the PK3K/Akt pathway, 
and doxorubicin, which causes cell death by DNA intercalation. All of the experiments 
were done with serum-free DMEM supplemented with P/S and 20 ng/mL of EGF and 
PDGF except for some experiments with spheroid in 10% FBS medium as indicated. For 
3D platform, single cells were encapsulated in PNIPAAm-PEG hydrogels and cultured 
for 14 days to induce spheroid formation (Figure 5.1B-E). Spheroids were then 
transferred to PEG-MAL gels of 10 and 20 wt. %, which were measured to be 3 and 5 
kPa (Figure 5.2). The similar fluorescent signals, which were determined by the 
fluorescent DNA-binding dye, between 3 and 5 kPa PEG-MAL gels indicate that the total 
amount of spheroids were evenly distributed (Figure 5.3).  
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Figure 5.1 Schematic of different types of platforms for drug screening. (A) Cells 
were laid on polystyrene 96-well plates and PEG-PC gels of different stiffnesses in 96-
well plate, or encapsulated in PEG-MAL gels of different stiffnesses as single cells or 
spheroids. Spheroids were treated with either serum medium or no-serum medium. Scale 
bars are 100 μm. Representative images of SkBr3 cells encapsulated in PNIPAAm-PEG 
hydrogel on day 1 (B) - (C) and day 14 (D) - (E).  
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Figure 5.2 Young's modulus of 10 and 20 wt % PEG-MAL hydrogels. 
 
 
 
 
 
 
 
 
 
 159 
 
3 5
0
200
400
600
Young's Modulus (kPa)
Fl
uo
re
sc
en
t i
nt
en
si
ty
 
0 2000 4000 6000 8000 10000
0
500
1000
1500
Cell count
Fl
uo
re
sc
en
t i
nt
en
si
ty
 
Figure 5.3 The amount of spheroids are similar between 3 and 5 kPa PEG-MAL 
gels. (A) The fluorescent intensity, which correlates with the amount of DNA, are the 
same. (B) The fluorescent intensity is linearly correlated with cell number.   
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 Drug resistance in spheroids can be mediated by the limitation of drug diffusion 
into the spheroids [20], and drug and oxygen diffusion can decrease significantly for 
tumor cells that were more than 60 μm from blood vessels [21]. Therefore, all spheroids 
were harvested when their size were around 100-150 μm in diameter (Figure 5.1E) to 
eliminate this possibility. For both cell lines, proliferation was quantified at the same time 
point as drug treatment. When analyzing the proliferation of SkBr3 across all platforms, 
the students' t-test, which was used to compare the proliferation between soft and stiff 
gels within the same platform, shows a significant increase in proliferation of monolayer 
cells on stiff 2D PEG-PC gels and a decrease in proliferation of single cell and spheroids 
in stiff 3D PEG-MAL gels as compared with the other modulus condition (Figure 5.4A). 
This observed opposite trend in proliferation between 2D and 3D platforms is consistent 
with other observations that cells proliferate more on 2D stiffer substrate [22,23] and in 
3D softer gels [24,25]. When comparing between 2D and 3D platforms (2D gels, 3D 
single cell and spheroids), two-way ANOVA analysis found that the change in platform 
was the larger driver of proliferation (35% of total variance, p < 0.0001), followed by 
modulus (10%, p < 0.0001) (Table 5.1). Proliferation on plastic could not be included in 
two-way ANOVA analysis because it had only one stiffness condition. When comparing 
the effect between medium and modulus (3D spheroids with and without FBS), two-way 
ANOVA analysis showed that the change in medium had a larger effect on total variance 
(56%, p < 0.0001)) than the change in modulus (3%, p = 0.064). When two-way ANOVA 
analysis was performed to the IC-50s of all 4 drugs in the same manner with proliferation 
data, both sorafenib (Figure 5.4B) and temsirolimus (Figure 5.4D) are strongly sensitive 
to platform (51% (p = 0.0018) and 80% (p = 0.0007) of total variance as opposed to 3% 
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(p = 0.2898 and 0.2404) from modulus for both sorafenib and tesmirolimus, respectively) 
and medium condition (81% (p < 0.0001)and 87% (p = 0.0006) of total variance as 
opposed to 2% (p = 0.168) and 0.3% (p = 0.7101) from modulus for sorafenib and 
temsirolimus, respectively). For both lapatinib (Figure 5.4C) and doxorubicin (Figure 
5.4E), although none of these three variables cause a significant difference in the IC-50s, 
the platform was found to affect the results more than modulus (35% (p = 0.0995) vs. 
10% (p = 0.2241) and 8% (p = 0.6956) vs. 2 % (p = 0.6735) of total variance for lapatinib 
and doxorubicin, respectively). Similarly, medium effected to results more than modulus 
(28% (p = 0.1688) vs. 0.08% (p = 0.9351) and 49% (p = 0.0526) vs. 0.01% (p = 0.9764) 
of total variance for lapatinib and doxorubicin, respectively). Overall, variations in 
platform and medium strongly affected how SkBr3s responded to sorafenib and 
temsirolimus, but not to lapatinib and doxorubicin. In addition, when one-way ANOVA 
was performed to compared the IC-50s across all conditions for all 4 drugs, spheroids in 
serum-supplemented medium were found to be most resistant to sorafenib and 
temsirolimus, but not to lapatinib and doxorubicin. Surprisingly, all variations with IC-
50s across all conditions were not correlated with proliferation (Figures 5.5A-D).  
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Figure 5.4 The responses of SkBr3 cells to drugs are dependent on drug types, 
platform, and medium condition. (A) The proliferation was quantified across multiple 
platforms. The students' t-test showed cells proliferated more on stiffer substrate in 2D 
and in softer substrate in 3D. One-way ANOVA analysis across all conditions showed the 
IC-50s of spheroids in serum medium were highest with (B) sorafenib and (D) 
temsirolimus, but did not change much with (C) lapatinib and (E) doxorubicin.  
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 Sensitivity to 
platform (%) 
(2D and 3D) 
Sensitivity to 
modulus (%) 
(2D and 3D) 
Sensitivity to 
medium (%) 
(spheroid only) 
Sensitivity to 
modulus (%) 
(spheroid only) 
Proliferation 35 (*) 10 (*) 57 (*) 3 
Sorafenib 51 (*) 3 81 (*) 2 
Lapatinib 35 10 28 0.08 
Temsirolimus 80 (*) 3 87 (*) 0.3 
Doxorubicin 8 2 49 0.01 
 
Table 5.1 Two-way ANOVA analysis of SkBr3 cells. Summary of  two-way ANOVA 
analysis of SkBr3s' IC-50s for sensitivity to platform, medium, and modulus. 
 
Sorafenib
0 6000 12000 18000 24000
0
10
20
30
40
PS
PEG-PC
Single cell
Spheroid
Spheroid (serum)
Spearman R = 0.52
p =  0.16
Proliferation (RLU)
IC
-5
0
(µ
M
)
Lapatinib
0 6000 12000 18000 24000
0
5
10
15
20
25 Spearman R = 0.63
p =  0.08
Proliferation (RLU)
IC
-5
0
(µ
M
)
Temsirolimus
0 6000 12000 18000 24000
0
20
40
60 Spearman R = 0.63
p =  0.08
Proliferation (RLU)
IC
-5
0
(µ
M
)
Doxorubicin
0 6000 12000 18000 24000
0
5
10
15 Spearman R = -0.52
p =  0.16
Proliferation (RLU)
IC
-5
0
(µ
M
)
 
Figure 5.5 Spearman correlation between IC-50s and proliferation of SkBr3s. There 
is not any significant correlation between the IC-50s and proliferation for all drugs: (A) 
sorafenib, (B) lapatinib, (C) temsirolimus, and (D) doxorubicin. 
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 Interestingly,  the proliferation of MDA-MB-231 cells also showed a similar 
modulus-dependent trend as SkBr3 cells, with cells proliferating more on 2D stiffer gels, 
and in 3D softer gels, as indicated by the student's t-test (Figure 5.6A). However, when a 
two-way ANOVA was performed as described above, both platform and medium 
appeared to affect the proliferation more than modulus (49% (p < 0.0001) vs. 0.8% (p = 
0.1329) and 59% (p < 0.0001) vs. 28% (p < 0.0001) of total variance for both platform 
and medium, respectively). For sorafenib (Figure 5.6B) and lapatinib (Figure 5.6C), 
platform, medium, and modulus significantly contributed to the variation in IC-50s (with 
the exception of modulus when compared with platform for sorafenib); however, 
platform and medium had a much larger effect on total variance than modulus (Table 
5.2). For temsirolimus (Figure 5.6D) and doxorubicin (Figure 5.6E), none of these 
parameters significantly affected the outcome of the IC-50; nevertheless, the modulus had 
a slightly larger effect on total variance than the platform and medium (with the 
exception of modulus when compared with medium for temsirolimus) (Table 5.2). One-
way ANOVA analysis of all IC-50s for 4 drugs indicated that spheroids in serum-
supplemented medium were most resistant to sorafenib and lapatinib, but not to 
temsirolimus and doxorubicin. Overall, platform, medium, and modulus significantly 
affected the 231s' IC-50s of sorafenib and lapatinib, but none of these had any impact on 
the IC-50s of temsirolimus and doxorubicin. In contrast to the SkBr3s, the variations in 
IC-50s of the 231s were positively correlated with the change in proliferation across 
different platforms for sorafenib, lapatinib, and temsirolimus (Figures 5.7A-C); however, 
similar to the SkBr3s, there was not a correlation between the IC-50 and proliferation for 
doxorubicin (Figure 5.7D).  
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Figure 5.6 The responses of MDA-MB-231 cells to drugs are dependent on drug 
types, platform, medium, and modulus conditions. (A) The proliferation was 
quantified across multiple platforms. The students' t-test showed cells proliferated more 
on stiffer substrate in 2D and in softer substrate in 3D. One-way ANOVA analysis across 
all conditions showed the IC-50s were strongly sensitive to platform and medium 
condition with (B) sorafenib and (C) lapatinib, but did not change much with (D) 
temsirolimus and (E) doxorubicin. 
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 Sensitivity to 
platform (%) 
(2D and 3D) 
Sensitivity to 
modulus (%) 
(2D and 3D) 
Sensitivity to 
medium (%) 
(spheroid only) 
Sensitivity to 
modulus (%) 
(spheroid only) 
Proliferation 49 (*) 0.8 59 (*) 28 (*) 
Sorafenib 91 (*) 2 96 (*) 2 (*) 
Lapatinib 76 (*) 14 (*) 86 (*) 9 (*) 
Temsirolimus 11 22 22 10 
Doxorubicin 1 11 27 37 
 
Table 5.2 Two-way ANOVA analysis of MDA-MB-231 cells. Summary of  two-way 
ANOVA analysis of MDA-MB-231s' IC-50s for sensitivity to platform, medium, and 
modulus. 
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Figure 5.7 Spearman correlation between IC-50s and proliferation of MDA-MB-
231s. There is a significant positive correlation between the IC-50s and proliferation for 
(A) sorafenib, (B) lapatinib, and (C) temsirolimus, but not with (D) doxorubicin. 
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5.4.2 Varying in IC-50 is dictated by cell-microenvironment interaction 
 Since the change in platform significantly affected how cells responded to certain 
types of drug, I quantified the difference in drug response between cells cultured in 3D 
and 2D to see if long-term culture in 3D could possibly cause a significant change in cell 
behavior that ultimately led to the results above. After 14 days of culture in PNIPAAm, 
SkBr3 and MDA-MB-231 spheroids were dissociated, placed on the plastic 96-well plate, 
and treated with drugs. The IC-50s were then compared to cells cultured in tissue culture 
flasks (Figure 5.8A). Strikingly, only SkBr3 cultured in 3D was 50% more resistant to 
sorafenib as opposed to cells cultured in 2D, and the rest of the IC-50s do not show any 
significant difference in drug response between cells cultured in 2D and 3D (Figures 5.8B 
and C). These results suggested that cell-drug interaction is strongly regulated by the 
immediate change in microenvironment/platform not long-term culture condition.    
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Figure 5.8 Long-term culture of spheroids in 3D PNIPAAm does not significantly 
change the nature of the cells. (A) Cells were cultured to form spheroids for 14 days, 
then the spheroids were removed from the gels, dissociated and seeded on the 96-well 
plates similarly to cells cultured in the tissue culture flask. Both SkBr3s (B) and MDA-
MB-231s (C) responded to drugs in a similar manner regardless of culture methods, 
except for that SkBr3 cells cultured in 3D were more resistant to sorafenib.    
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5.4.3 SkBr3's response to EGF in 3D is independent of stiffness 
 Cells on stiff 2D substrates were not only more proliferative, but also previously 
shown to be more sensitive to EGF stimulation by me [16] and others [26,27]. Since 
serum medium contains EGF and many other growth factors, and SkBr3 spheroids 
proliferated significantly more in softer gels with serum (Figure 5.4A), I quantified the 
response of spheroids to EGF at different stiffness conditions to see if growth factor 
stimulation was responsible for the observed difference in proliferation. Encapsulated 
SkBr3 spheroids in 3 and 5 kPa gels were stimulated with EGF for an hour, then the EGF 
medium was replaced with serum-free medium (Figure 5.9A). The phosphorylation of 7 
different RTK receptors (HGFR, EGFR, HER2, HER3, HER4, IGF1R, IR) were 
quantified by using a multi-plex MAGPix system; however, only signals from 
phosphorylated EGFR, HER2, HER3 were detected. In contrast to observations on 2D 
substrates, phosphorylation of EGFR was similar between the two stiffnesses. The 
phosphorylation peaked at 10 min after stimulation, then decreased over time (Figure 
5.9B). The phosphorylation of HER2 reduced to a minimum at 30 min and 60 min for 3 
and 5 kPa gels, respectively  (Figure 5.9C). Similar to this trend, the phosphorylation of 
HER3 in the 3 kPa gels decreased to a minimum at 60 min and remained low (Figure 
5.9D); however, HER3 phosphorylation in the 5 kPa gels did not change significantly 
across all time points. Although there were minor differences in phosphorylation of 
HER2 at 24 h and HER 3 at 7 h time points, the phosphorylation levels of HER2 and 
HER3 across other time points were similar between the soft and stiff gels. When 
comparing the phosphorylation of similar RTK receptors between the encapsulated 
spheroids in PEG-MAL gel and the unencapsulated spheroids, only signals from 
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phosphorylated EGFR, HER2 and HER3 were detected. Strikingly, the encapsulation 
significantly reduced the phosphorylation of  EGFR and HER3 (Figure 5.9E-F), whereas 
HER2 phosphorylation remained unchanged (Figure 5.9G). This result emphasized the 
role of  the surrounding microenvironment in influencing the activity of certain RTK 
receptor such as EGFR and HER3. 
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Figure 5.9 The response of SkBr3 spheroids to EGF in 3D is stiffness independent. 
(A) Encapsulated spheroids in PEG-MAL gels were serum-starved for 24 h before 
stimulating with 100 ng/mL of EGF. After 1 h, EGF medium was replaced with serum-
free medium. (B) EGFR phosphorylation peaked at 10 min and decreased over time. Both 
(C) HER2 and (D) HER3 phosphorylation decreased during the EGF stimulation and 
remained low even after EGF removal. Although there was a significant decrease in (E) 
EGFR and (F) HER3 phosphorylation post encapsulation, there was not any significant 
change in (G) HER2 phosphorylation due to encapsulation. Statistics are with respect to 
time 0. 
B
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5.4.4 Long-term exposure of SkBr3 to lapatinib results in different signaling 
pathways activated in 2D and 3D  
 Since there was not any significant change in IC-50s across all platforms after 
short term exposure of SkBr3s to lapatinib (Figure 5.4C), this motivated me to investigate  
the influence 2D and 3D platforms on SkBr3s after being treated with lapatinib over a 
long time period. SkBr3s were seeded on 2D plastic plates or encapsulated in PNIPAAm, 
and then treated with lapatinib or DMSO control over 14 days. They were serum-starved 
before being simulated with 10% FBS medium for 15 minutes. Phosphorylation of 
EGFR, HER2, HER3, HER4, IGF1R, and IR were detected, whereas HGFR 
phosphorylation was equal to the blank. Interestingly, lapatinib treated cells had 
significantly lower phosphorylation of EGFR, HER2 and HER3 in both 2D and 3D as 
compared with the control (Figures 5.10A-C). However, the IR phosphorylation of 
lapatinib treated cells was significantly higher than the control in 2D, but similar to the 
control in 3D (Figure 5.10D). The phosphorylation of HER4 and IGF1R were the same 
between the control and treated cells for both 2D and 3D (Figures 5.10E-F). When 
quantifying the downstream signaling molecules ERK, JNK, and Akt for the same 
samples, strikingly, the phophorylation pattern of JNK (Figure 5.11A) was similar to that 
of EGFR (compare Figures 5.10A and 5.11A). Both had a significant higher 
phophorylation level of 2D control cells as opposed to the rest of the conditions (one-way 
ANOVA). JNK phosphorylation was lower for lapatinib treated cells in 2D, but it was not 
significantly different between the control and treated cells in 3D. ERK phosphorylation 
displayed an opposite trend with lapatinib treated cells higher in 2D and lower in 3D 
(Figure 5.11B), and there was not any difference in Akt phosphorylation between the 
 173 
 
control and treated cells in both 2D and 3D. Although the change in platfrom did not 
cause any significant difference in SkBr3 response to lapatinib for a short-term exposure, 
the type of platform did influence the activity of several signaling molecules (IR and 
ERK)  in SkBr3 cells after long-term exposure to lapatinib. 
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Figure 5.10 Phosphorylation of RTK receptors of SkBr3 cells under serum 
stimulation.  Cells were cultured in 2D plastic plate or encapsulated in 3D PNIPAAm. 
Cells were treated with 1.25 uM of lapatinib or DMSO control for 14 days followed by 
serum-starvation and serum-stimulation. Phosphorylation level of (A) EGFR, (B) HER2, 
and (C) HER3 in lapatinib treated cells decreased in both 2D and 3D as compared with 
the control. Lapatinib treated cells had increased (D) IR phosphorylation in 2D but not in 
3D, and there was not any significant difference in phosphorylation between lapatinib 
treated cells and the control in both 2D and 3D for (E) IGF1R and (F) HER4. 
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Figure 5.11 Signaling of ERK, JNK, and Akt in SkBr3 cells under serum 
stimulation. (A) phosphorylation of JNK significantly decreased in lapatinib treated cells 
in 2D, but not in 3D, as compared with the control. (B) ERK phosphorylation increased 
in 2D and decreased in 3D for lapatinib treated cells, whereas (C) Akt phosphorylation 
did not change.  
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5.5 Discussion 
 I have identified that the IC-50s of SkBr3s treated with either sorafenib or 
temsirolimus and 231s treated with either sorafenib or lapatinib were sensitive to the 
change in platform and medium. The IC-50s of both cell lines were insensitive to the 
change in platform or medium when treated with doxorubicin, which induces cell death 
by DNA intercalation and topoisomerase II inhibition. Although spheroids can capture 
many microenvironmental features of an in vivo tumor [28], cells in spheroids are not 
neccessarily more drug resistant than cells cultured on monolayers. Ewing sarcoma tumor 
cells cultured to form spheroids in 3D PCL scaffolds were 228-fold more resistant to 
doxorubicin than 2D monolayer cells, and this is not due to poor drug penetration into the 
innermost cell layer [29]. However, ovarian cancer spheroids grown in PEG-based 
hydrogels were approximately 2.5-fold more resistant  to cisplatin than 2D monolayer, 
which causes apoptosis by crosslinking DNA [6]. Camptothecin (inhibitor to 
topoisomerase I), fluorouracil (inhibitor to DNA synthesis) [30], and some derivatives of 
imidazoacridinone (inhibitor to topoisomerase II) [31] were found to have similar 
cytotoxic effects to cells cultured as monolayers or as spheroids. Thus, multiple different 
drugs, which share similar targets (DNA intercalation or topoisomerase inhibition), can 
have different or similar cytotoxic effects to cells in monolayer or spheroid. In my case, I 
observed that doxorubicin had a similar effect on both cell types across all testing 
platforms. 
  Interestingly, variations in both platform and medium were found to have large 
effects on both cell lines when treated with sorafenib. ERK signaling, which is targeted 
by sorafenib, was implicated in ECM stiffening in both 2D and 3D [26,32,33], and cancer 
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cells on stiffer substrates were more resistant to sorafenib [16]. This suggests that the 
Raf/MEK/ERK pathway could be sensitive to the change in microenvironment. Indeed, 
both cell lines' response to sorafenib were highly sensitive to the type of platform. The 
Raf/MEK/ERK pathway is also one of the key downstream signaling pathways of RTK 
receptors [34], which can be activated by growth factors in serum. This could be an 
explanation for the sensitivity of both cell lines to medium when treated with sorafenib.  
 Although PI3K/Akt/mTOR is another major signaling pathway downstream of 
RTK activation [34], only SkBr3 spheroids showed higher IC-50s when treated with 
temsirolimus, which inhibits mTOR, in serum supplemented medium (Figure 5.4D). 
Moreover, the temsirolimus IC-50s of  SkBr3 cells were more sensitive to variation in 
platform than 231 cells. Both Raf/MEK/ERK and PI3K/Akt/mTOR pathways are 
responsible for proliferation of HER2-overexpressing cells [35], whereas 
Ras/Raf/MEK/ERK could be the main driver of 231 cell proliferation due to its B-Raf 
and K-Ras mutation [36,37]. In the basal signaling protein profiles identified by Niepel et 
al., phosphorylated Akt in the SkBr3s is nearly 40-fold higher than the 231s, whereas 
phosphorylated ERK is similar for both cell types [38]. SkBr3 cells were shown to switch 
from PI3K/Akt signaling to MEK/ERK signaling in 3D Matrigel, whereas both pathways 
were activated in 2D [39], and inhibition of PI3K resulted in enhanced MEK/ERK 
signaling [40]. These reports support my observation that inhibition of Akt/mTOR 
signaling in SkBr3s, but not 231s, was sensitive to the change in platform.    
 When treating with lapatinib, which targets both HER2 and EGFR, 231s’ IC-50s  
were sensitive to variations in both platform and medium. Since 231 cells overexpress 
EGFR [41,42], it can be implied that EGFR signaling in 231 cells is sensitive to the type 
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of platform and medium. Luca et al. also found that many colorectal cancer cell lines had 
lower EGFR gene expression when cultured in 3D laminin-rich ECM [43]. SkBr3 
response to lapatinib was insensitive to the change in both platform and medium. Thus, it 
can be implied that the activities of EGFR and HER2 in SkBr3s were not sensitive to the 
change in platform and medium. Further experiments confirmed that HER2 
phosphorylation was not sensitive to modulus (Figure 5.9C), nor encapsulation (Figure 
5.9 F), nor platform (2D vs. 3D in Figure 5.10B). EGFR phosphorylation of SkBr3 in 3D 
was not affected by stiffness (Figure 5.9B), whereas EGFR phosphorylation was higher 
on stiffer substrates [26], its phosphorylation on 2D plastic surface was 7-fold higher than 
in 3D gels (Figure 5.10A). However, in SkBr3 cells, EGFR protein expression was much 
lower than 231 cells, and their HER2 protein expression was very high [42]. Thus, the 
signaling from HER2 may outweigh the effect from EGFR signaling in SkBr3s. As a 
result, the IC-50s of lapatinib treated SkBr3 were less sensitive to the change in 
microenvironment as opposed to those of 231 cells, which express only EGFR. 
 Unlike HER2 phosphorylation, which was not sensitive to the change in the 
surrounding microenvironment, HER3 phosphorylation in SkBr3 spheroids decreased 
significantly upon encapsulation (Figure 5.9E). Among the HER-family, HER3 is the 
only member that does not have tyrosine kinase activity upon binding its ligand 
heregulin, and it needs to heterodimerize with the other HER-family members in order to 
be activated [44]. In 2D, HER3 was found to heterodimerize with HER2 as an oncogenic 
unit to drive tumor cell proliferation [45]. It is possible that encapsulation could disrupt  
the heterodimerization of HER3 and lead to a decrease in its phosphorylation, and this 
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could cause an attenuation of  the downstream PI3K/Akt signaling. In fact, Weigelt et al. 
found that Akt phosphorylation of  SkBr3s in 3D Matrigel was abolished [39]. 
 Reduction of EGFR and HER3 phosphorylation during cell encapsulation  may 
have a profound impact on future research of HER-family receptors. Various methods 
has been developed to induce 3D spheroid formation by allowing cell aggregation on 
non-adherent surfaces such as the hanging drop method [46], agarose [9] or PDMS [10] 
coated plates, or thin film PDMS micropatterning [15]. An encapsulation model may be 
more relevant because tumor cells are tightly packed within the tumor microenvironment, 
and encapsulation status could affect the activity of certain RTK receptors such as EGFR 
and HER3. 
 Interestingly, during EGF stimulation, both HER2 and HER3 phosphorylation 
decreased concurrently with EGFR activation. It is common that EGFR, upon EGF 
binding, will heterodimerize with HER2 and subsequently lead to phosphorylation in 
both receptors that results in activation of PI3K/Akt and Ras/Raf/MEK/ERK pathways 
[35]. What I observed here suggests a mechanism of EGFR homodimerization and 
possibly a disruption of HER2-HER3 complexes, which leads to a reduction in 
phosphorylation level of both receptors. Similarly, after EGF stimulation in 2D, 
Brockhoff et al. found a formation of EGFR-HER2 receptors complexes with BT474 
cells, but not with SkBr3 cells, and the authors suggested an EGFR-EGFR 
homodimerization mechanism in SkBr3 cells due to the higher number of available 
EGFRs on the surface of these cells [47]. However, the authors observed a high amount 
of HER2-HER3 heterodimers and constitutively activated Akt regardless of stimulation. 
Taken together, these results also support my previous conclusion regarding the 
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sensitivity of HER2-HER3 interaction to the surrounding encapsulating 
microenvironment. Although the phosphorylation of SkBr3 spheroids under EGF 
stimulation is independent of modulus, SkBr3 spheroids in the soft gels proliferated 
significantly more than those in stiffer gels, and this trend was consistent with the 231s, 
and from others [24,25]. This effect can be attributed to the larger solid stress in stiffer 
gels, and this stress on the spheroids can limit the spheroid proliferation [48–50]. The in 
vivo tumor is also subjected to solid stress induced by stiff collagen fibers, which provide 
tensile strength to the tissue, and hyaluronic acid, which provides the compressive 
resistance due to its ability to hold water [51]. Thus, it is necessary to take into account 
the effect from the solid stress as this can influence cell response to drug treatment, and 
this solid stress is lacking from unencapsulated spheroid models. 
 Although short term exposure to lapatinib across various 2D and 3D platforms did 
not show any significant variation in IC-50, long-term exposure to lapatinib showed some 
differences in phosphorylation of certain signaling molecules across 2D plastic plate and 
3D PNIPAAm. Upon serum stimulation, phosphorylation levels of EGFR, HER2, and 
HER3 in lapatinib treated cells were significantly lower than the control for both 
platforms, and Jegg et al. also observed similar phenomena with long-term lapatinib-
treated SkBr3 on 2D [52]. However, IR phosphorylation of lapatinib-treated cells in 2D 
increased significantly compared with the control but not in 3D (Figure 5.10D). Since IR 
is capable of activating downstream signaling pathways such as Ras/Raf/MEK/ERK and 
PI3K/Akt/mTOR [53], this corresponds with the increase in downstream ERK activation 
in lapatinib treated cells in 2D (Figure 5.11B). Liu et al. identified the activation of Akt 
and ERK due to an upregulation of  the upstream AXL receptor as a mechanism for 
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survival of lapatinib resistance BT474 cells in 2D [54], whereas Jegg et al. identified the 
activation of mTOR independent of PI3K/Akt signaling as a mechanism for lapatinib 
resistance in SkBr3 cells. However, the methods of  creating lapatinib resistant cells 
between the authors were also really different. In my case, exposure to lapatinib for 14 
days was not long enough to create an established lapatinib resistant cell line (Figure 
5.12) despite similar observable trends, which EGFR, HER2, and HER3 was down-
regulated in long-term lapatinib treated cells, with both Liu et al. and Jegg et al.. 
Nevertheless, 14 days of lapatinib exposure was enough for me to see a different pattern 
of SkBr3 response between 2D and 3D with IR and ERK activation. The pattern of EGFR 
activation was similar to JNK activation with very high phosphorylation on 2D and low 
phosphorylation in 3D. This could be indicative of EGFR activating JNK under EGF 
stimulation since EGF stimulation is known to activate PI3K/Akt and 
Ras/Raf/MEK/ERK [55] as well as JNK through Ras/Rac1 pathway [56,57]. 
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Figure 5.12 Lapatinib treated and DMSO control SkBr3 spheroids have similar IC-
50s. SkBr3s were cultured in PNIPAAm for 6 days (DMSO) and 14 days (lapatinib) to 
create spheroids of similar sizes since cells cultured with lapatinib grew at a slower rate. 
Spheroids were transfered to 3 kPa gels and treated with laptinib.     
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5.6 Conclusions 
 Overall, through testing 3 targeted drugs and 1 cytotoxic drug with 2 cell lines 
across multiple platforms, I found that the sensitivity of cell-drug interaction to the 
platform or medium is dependent on both drug type and cell type. The IC-50s of SkBr3s 
were sensitive to platform type when treated with temsirolimus and sorafenib. The IC-50s 
of 231s were sensitive to platform type when treated with sorafenib and lapatinib. 
Variation in platform did not matter for both 231s and SkB3s when treated with 
doxorubicin. I also found that HER3 and EGFR activation were sensitive to the 
surrounding microenvironment, whereas HER2 phosphorylation is not. Long-term 
exposure of SkBr3 to lapatinib caused distinct patterns of IR and ERK signaling observed 
in 2D, but not in 3D. My results highlight the importance of understanding the cell type 
and drug mechanism in choosing the relevant biomaterial system for studying of cell 
response to drugs.    
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CHAPTER 6 
 
SUMMARY AND CONCLUSIONS 
 
6.1 Summary 
 Throughout this thesis, the hypothesis that the physicochemical cues from the 
ECM can promote drug resistance in cancer cells has been tested. First, various 2D and 
3D biomaterial systems were developed and applied to test the hypothesis. Second, 
cancer cells' response to sorafenib on 2D biomaterials with varying material and integrin 
binding properties were probed. Finally, cancer cells were tested with different drugs 
across various types of 2D and 3D microenvironments. 
6.1.1 Biomaterial platforms 
 In Chapter 2, a novel hydrophilic material, PEG-PC, was developed, and its 
properties were characterized. The hydrogel system was shown to have a tunable 
mechanical range from 1 to 10,000 kPa and more hydrophilic than PEG alone. Different 
methods were utilized to couple full-length matrix proteins to the gel surface. Chapter 3 
described the adaptation of PEG-PC, PEG, and PAA hydrogels to the 96-well plate 
format for high-throughput applications. Matrix proteins were coupled to these hydrogels 
in the 96-well plate by using a heterobifunctional crosslinker. The gels' moduli were 6, 
23, 50, 165, and 400 kPa. Chapter 5 detailed the adaptation of 3D biomaterial systems. 
PNIPAAm-PEG is a thermal-reversible gel which was used to support the long-term 
culture and formation of 3D spheroids. Cell-drug interaction in 3D was studied with cells 
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or spheroids encapsulated in the PEG-MAL gels. The mechanical property of this 3D gel 
system was tunable, and two different moduli being used were 3 and 5 kPa. Short 
bioactive peptide sequence CRGD was also incorporated into the PEG-MAL gel system. 
6.1.2 Matrix stiffness and integrin binding regulate the drug response in 2D  
 As described in chapter 3 and 4, most of cell lines were more resistant to 
sorafenib when binding to collagen-rich matrix as compared with binding to basement 
membrane matrix. Chapter 4 detailed the response of similar cell lines to sorafenib when 
placed on 2D high-throughput platforms coupled with either collagen-rich or basement 
membrane ECM. Cells on stiffer gels were more resistant to sorafenib than those on 
softer gels. Although cells on stiffer gels are known to be more proliferative, this 
stiffness-induced drug resistance was found to be independent of proliferation and not 
related to the canonical Rho-ROCK pathway. Instead, this drug resistance was mediated 
by β1 integrin and JNK activation, and co-administering sorafenib with inhibitor to either 
of β1 integrin or JNK abolished the stiffness-induced drug resistance. 
6.1.3 The role of biomaterial platforms in controlling cellular response to drugs 
 Chapter 5 described the studying of cell-drug interaction across varying types of 
2D and 3D platforms and identified that the sensitivity of cell-drug interaction to 
microenvironment is dependent on both drug type and cell type. Although cell response 
to drug was found to be strongly regulated by material modulus in 2D, the effect on the 
IC-50s from changing platforms and medium outweighed the effect from varying 
modulus when comparing across different types of platform, medium, and modulus. 
Changing in platform and medium affects how SkBr3 cells' response to sorafenib and 
temsirolimus, and 231 cells' response to sorafenib and lapatinib, whereas both cell types' 
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response to doxorubicin are independent of platform, medium, and modulus conditions. 
Both HER3 and EGFR receptors were found to be sensitive to the microenvironment, but 
not HER2 receptor. 
6.2 Conclusions 
 The results presented in this dissertation support the hypothesis that the 
interaction between cancer cells and the microenvironment can mediate survival signals 
to cancer cells in the presence of chemotherapeutics. The stiffness-induced sorafenib 
resistance on 2D substrates is independent of the change in cytoskeletal networks that 
could influence the canonical Rho/ROCK signaling, but instead depending on β1 integrin 
and JNK activation. This finding elucidates  a new mechanism through which 2D matrix 
stiffness can modulate cell behavior through pathways that are not related to those that 
regulate cytoskeletal assembly. In 3D, matrix stiffness does not affect the drug response 
as much as other factors such as cell-cell contact or medium condition, and the influence 
of these factors to drug response is also dependent on drug type and cell type. 
 The results from this dissertation can have a great impact on future research 
regarding developing preclinical models for cancer drug discovery. First, a better 
understanding of how biomaterial platforms regulate drug response in cancer cells may 
guide future effort in designing better model for preclinical drug development, and 
having the relevant preclinical model that is more predictive of in vivo outcome will save 
both time and money. Secondly, this research has created and applied separate in vitro 
model systems including a novel biomaterial with an extremely wide mechanical range 
that is suitable for many other applications, various 2D high-throughput biomaterial 
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platforms for studies of cell-drug interaction and mechanobiology, a 3D biomaterial 
system to culture multi-cellular spheroids, and a 3D spheroid model which can be easily 
tunable for mechanical, integrin binding, and MMP-degradable properties. 
6.3 Future Considerations 
6.3.1 Matrix stiffening and inflammation 
 As shown previously in Chapter 4, matrix stiffening triggers higher JNK 
phosphorylation. Activation of JNK in hepatocyte is known to stimulate its production of 
high-mobility group box 1 protein (HMGB1), S100 calcium binding proteins, heat-shock 
proteins, and purine metabolites that can activate IKK-β and NF-κB of local Kuffer cells 
and trigger these cells to produce pro-inflammatory cytokines [1]. Activation of JNK in 
macrophages can inhibit the function of glucocorticoid receptors, thereby allowing NF-
κB to be activated and enhancing the production of proinflammatory cytokines and 
chemokines by these cells [2]. The pro-inflammatory cytokines can promote the tumor 
cell growth and attract the infiltration of other immune cells, and this infiltration in turn 
makes the tumor microenvironment more inflammatory, which could exacerbate the 
disease [3,4]. It is proposed here that activation of JNK in 231s on stiff substrate can 
make these cells produce more pro-inflammatory cytokines and other factors. 
Examination of condition medium of these cells cultured on stiff substrates may provide 
insights into this phenomena.        
6.3.2 Apoptotic signaling on stiffen matrix 
 In Chapter 4, cells on stiff substrates were shown to be more resistant to 
sorafenib, and this was found to be independent of Rho/ROCK signaling and 
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proliferation. JNK activation was found to be responsible for the survival of 231s, but not 
SkBr3s. Both MAPK and Akt signaling in SkBr3 was not responsible for this cell line's 
resistance to sorafenib. It is proposed that the down regulation of apoptotic signals 
instead of activation of survival pathways  could be responsible for sorafenib resistance 
of SkBr3s on stiff substrates. Caspases are known to mediate intracellular apoptosis. 
Caspases-8 and -10 are activated upon binding of death-inducing ligands such as FasL 
and TNF [5], but in my case, these ligands were not included in the experiment. Thus, 
down regulation of intrisic death pathway mediated by caspase-9 and downstream 
caspase-3/-6/-7 [5] could be responsible for promoting sorafenib resistance. Growth 
arrest could be another mechanism for survival of drug resistance cells. Activation of 
CDK1 is important for cells to enter into M phase, which includes mitosis and 
cytokinesis, from G2 phase [6]. Therefore, activity of CDK1 also should be probed in 
order to truly understand the mechanism of sorafenib resistance. 
6.3.3 Cadherin-mediated cell-cell contact and drug resistance 
 In Chapter 5, SkBr3 spheroids were observed to be much more resistant to 
sorafenib, lapatinib, and temsirolimus than SkBr3 single cells. However, 231 spheroids's 
IC-50s do not show a profound difference with  single cells' IC-50s as much as those of 
SkBr3 cells . It is proposed that cadherin-mediated cell-cell contact can promote a 
stronger drug resistance in SkBr3 cells than in 231s cells. 231 is a more aggressive cell 
type that can invade local tissue and metastasize distal organs; thus it could be infer that 
survival of these cells can be less dependent on cell-cell contact as opposed to the less 
aggressive SkBr3s. SkBr3s on monolayer do not express any of the major cadherins such 
as E-cadherin, N-cadherin, P-cadherin, cadherin-11, whereas 231s only express cadherin-
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11 [7]. However, SkBr3s were capable of forming tight spheroids in my 3D culture 
system. Thus, the expression of cadherin in 3D and 2D can be different depending on the 
microenvironment. Quantifying the expression of cadherins of these two cell types under 
conditions as monolayer, single cell in 3D, and spheroid can provide insights into how 
microenvironment regulates cadherin expression. Ligation of cadherins can mediate β-
catenin signaling, and cadherins can also interact with other RTKs and subsequently 
trigger survival pathways such as PI3K/Akt or MAPK [8]. These downstream signaling 
pathways should be quantified to understand how microenvironment induces cadherin 
expression and its downstream signaling. 
6.3.4 Cell-cell communication and drug resistance 
 The interaction between tumor cells and other factors released by different cell 
types can impart resistance to chemotherapeutics such as HGF is known to mediate 
vemurafenib resistance [9,10]. Cancer associated fibroblasts also play a role in promoting 
the growth of tumor cells [11]. Thus, it is important to identify the influence of fibroblast 
in the spheroid formation. The 3D PNIPAAm culture system allows tumor cells to be co-
cultured with fibroblasts, which can be seeded on the plate surface. Tumor spheroids can 
be collected separately from fibroblasts. A thorough examination of spheroids from co-
culture and mono-culture would include a gene expression analysis via reverse 
transcription polymerase chain reaction (RT-PCR) or real-time quantitative reverse 
transcription PCR (qRT-PCR), and their drug response should also be tested. Conditioned 
medium of the co-culture system should be quantified with the Luminex assays and 
compared with the mono-culture of spheroid and fibroblast alone. The drug response of 
spheroids from the co-culture and mono-culture systems should also be tested and related 
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to the gene expression results in order to identify the molecular targets that could be 
responsible for the differences. 
6.3.5 Nuclear shape and drug resistance 
 The enlargement of the nucleus was found to be associated with poorer prognosis 
in breast cancer as the nuclear area increased with disease progression [12]. The change 
in nuclear shape allows different rearrangements of chromatins, which may allow or 
prohibit  the accessibility of transcription factors to certain locations of the chromatins for 
gene transcription. Thus, certain genes can be upregulated or downregulated, and this 
results in different cell behaviors, and perhaps their response to drugs. Indeed, the 
increase in nuclear volume and chromatin decondensation were found to be highly 
correlated with DNA synthesis in endothelial cells [13], and smooth muscle cells that had 
larger nuclear area were found to proliferate more [14]. Since cells in advanced stage of 
breast cancer tend to be more drug resistant than those in earlier stage, it is proposed that 
cells with larger nuclear areas can be more resistant to chemotherapeutics than those with 
smaller areas.  Preliminary data showed that the nuclear area and perimeter of cells are 
changed when treating with doxorubicin (Figure 6.1A-D) and sorafenib (Figure 6.2A-D). 
However, the trend was different between the two cell types, and the nuclei of cells 
treated with doxorubicin had larger changes than those of cells treated with sorafenib 
partially due to different drug's mechanisms. Doxorubicin is a chemotherapeutic drug that 
can cause cell death by DNA intercalation and has to be localized in the nucleus to be 
effective, whereas sorafenib is a kinase inhibitor that can inhibit Raf kinase in the 
cytoplasm. Based upon these observations, drug treatment can cause a change in cellular 
nucleus, thus, it is possible to infer the reverse that the change in the nucleus can also 
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affect the effectiveness of drug treatment, especially the drugs that have to localize in the 
nucleus to be effective. Micro-contact printing can be employed to pattern glass surface 
with square or circular shapes that have different areas to control cell spreading, which in 
turn controls the nuclear area. The change in cell spreading can alter the ratio of lamin A 
and B, thereby affecting the nuclear mechanics, shape, and area; these changes play an 
important role in cell proliferation and differentiation [15]. Thus, the relative of amount 
lamin A and B of cells with different spreading area should be quantified. A partial 
knock-down of lamin A (with siRNA) of cells with the same spreading area can also be 
done to eliminate the effect of changing the cytoskeleton outside of the nucleus due to the 
change in cell shape. 
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Figure 6.1 The change in nuclear shape and area as a function of doxorubicin 
treatment. Increasing in doxorubicin concentration increases 231s' (A) nuclear area and 
(B) perimeter while decreasing Hs-578Ts' (C) nuclear area and (D) perimeter. 
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Figure 6.2 The change in nuclear shape and area as a function of sorafenib 
treatment. Increasing in sorafenib concentration slightly decreases 231s' (A) nuclear area 
and (B) perimeter while slightly increasing Hs-578Ts' (C) nuclear area and (D) perimeter. 
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